国内・海外ã®å¸‚å ´èª¿æŸ»ãƒ¬ãƒãƒ¼ãƒˆè²©å£²
- レãƒãƒ¼ãƒˆä¸€è¦§
Warning (2): session_start() [<a href='function.session-start'>function.session-start</a>]: open(/tmp//sess_b61c765e8dfd0e2cf6d6b2bc70fff848, O_RDWR) failed: Disc quota exceeded (69) [CORE/Cake/Model/Datasource/CakeSession.php, line 745]Code Context$limit = 'must-revalidate'session_start - [internal], line ?? CakeSession::_startSession() - CORE/Cake/Model/Datasource/CakeSession.php, line 745 CakeSession::start() - CORE/Cake/Model/Datasource/CakeSession.php, line 219 CakeSession::write() - CORE/Cake/Model/Datasource/CakeSession.php, line 439 SessionComponent::write() - CORE/Cake/Controller/Component/SessionComponent.php, line 55 CategoriesController::detail() - APP/Controller/CategoriesController.php, line 451 ReflectionMethod::invokeArgs() - [internal], line ?? Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 499 Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193 Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167 [main] - APP/webroot/index.php, line 118
Warning (2): session_start() [<a href='http://php.net/function.session-start'>function.session-start</a>]: Cannot send session cookie - headers already sent by (output started at /home/spi-information/www/lib/Cake/Utility/Debugger.php:797) [CORE/Cake/Model/Datasource/CakeSession.php, line 745]Code Context$limit = 'must-revalidate'session_start - [internal], line ?? CakeSession::_startSession() - CORE/Cake/Model/Datasource/CakeSession.php, line 745 CakeSession::start() - CORE/Cake/Model/Datasource/CakeSession.php, line 219 CakeSession::write() - CORE/Cake/Model/Datasource/CakeSession.php, line 439 SessionComponent::write() - CORE/Cake/Controller/Component/SessionComponent.php, line 55 CategoriesController::detail() - APP/Controller/CategoriesController.php, line 451 ReflectionMethod::invokeArgs() - [internal], line ?? Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 499 Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193 Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167 [main] - APP/webroot/index.php, line 118
Warning (2): session_start() [<a href='http://php.net/function.session-start'>function.session-start</a>]: Cannot send session cache limiter - headers already sent (output started at /home/spi-information/www/lib/Cake/Utility/Debugger.php:797) [CORE/Cake/Model/Datasource/CakeSession.php, line 745]Code Context$limit = 'must-revalidate'session_start - [internal], line ?? CakeSession::_startSession() - CORE/Cake/Model/Datasource/CakeSession.php, line 745 CakeSession::start() - CORE/Cake/Model/Datasource/CakeSession.php, line 219 CakeSession::write() - CORE/Cake/Model/Datasource/CakeSession.php, line 439 SessionComponent::write() - CORE/Cake/Controller/Component/SessionComponent.php, line 55 CategoriesController::detail() - APP/Controller/CategoriesController.php, line 451 ReflectionMethod::invokeArgs() - [internal], line ?? Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 499 Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193 Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167 [main] - APP/webroot/index.php, line 118
Warning (2): Cannot modify header information - headers already sent by (output started at /home/spi-information/www/lib/Cake/Utility/Debugger.php:797) [APP/View/Layouts/spi-information.ctp, line 2]Code Context$viewFile = '/home/spi-information/www/app/View/Layouts/spi-information.ctp' $dataForView = array( 'favorite_data' => array(), 'keywords' => array( (int) 0 => '急性骨髄性白血病治療薬', (int) 1 => '予測' ), 'summary' => array(), 'rrc' => array( (int) 0 => array( 'ReportRelationCategory' => array( [maximum depth reached] ) ), (int) 1 => array( 'ReportRelationCategory' => array( [maximum depth reached] ) ) ), 'rrr_report_base_res' => array(), 'report_detail' => array( (int) 0 => array( 'id' => '46865', 'order_num' => '1', 'report_id' => '39052', 'title' => '目次', 'body' => '<p> <span style="font-weight:bold;">Table of Contents</span> </p> <p> <span style="font-weight:bold;">Chapter 1. Methodology and Scope</span> <br /> 1.1. Market Segmentation & Scope<br /> 1.2. Segment Definitions<br /> 1.2.1. Disease<br /> 1.2.2. Treatment<br /> 1.2.3. Route of Administration<br /> 1.2.4. End Use<br /> 1.2.5. Regional scope<br /> 1.2.6. Estimates and forecasts timeline<br /> 1.3. Research Methodology<br /> 1.4. Information Procurement<br /> 1.4.1. Purchased database<br /> 1.4.2. GVR’s internal database<br /> 1.4.3. Secondary sources<br /> 1.4.4. Primary research<br /> 1.4.5. Details of primary research<br /> 1.4.5.1. Data for primary interviews in North America<br /> 1.4.5.2. Data for primary interviews in Europe<br /> 1.4.5.3. Data for primary interviews in Asia Pacific<br /> 1.4.5.4. Data for primary interviews in Latin America<br /> 1.4.5.5. Data for Primary interviews in MEA<br /> 1.5. Information or Data Analysis<br /> 1.5.1. Data analysis models<br /> 1.6. Market Formulation & Validation<br /> 1.7. Model Details<br /> 1.7.1. Commodity flow analysis (Model 1)<br /> 1.7.2. Approach 1: Commodity flow approach<br /> 1.7.3. Volume price analysis (Model 2)<br /> 1.7.4. Approach 2: Volume price analysis<br /> 1.8. List of Secondary Sources<br /> 1.9. List of Primary Sources<br /> 1.10. Objectives </p> <p> <span style="font-weight:bold;">Chapter 2. Executive Summary</span> <br /> 2.1. Market Outlook<br /> 2.2. Segment Outlook<br /> 2.2.1. Disease outlook<br /> 2.2.2. Treatment outlook<br /> 2.2.3. Route of Administration outlook<br /> 2.2.4. End Use outlook<br /> 2.2.5. Regional outlook<br /> 2.3. Competitive Insights </p> <p> <span style="font-weight:bold;">Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope</span> <br /> 3.1. Market Lineage Outlook<br /> 3.1.1. Parent market outlook<br /> 3.1.2. Related/ancillary market outlook<br /> 3.2. Market Dynamics<br /> 3.2.1. Market driver analysis<br /> 3.2.1.1. Increasing prevalence of acute myeloid leukemia<br /> 3.2.1.2. Advancements in diagnostic techniques<br /> 3.2.1.3. Growing investments in R&D techniques<br /> 3.2.2. Market restraint analysis<br /> 3.2.2.1. High cost of treatment<br /> 3.2.2.2. Limited treatment options<br /> 3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools<br /> 3.3.1. Industry Analysis - Porter’s Five Forces<br /> 3.3.1.1. Supplier power<br /> 3.3.1.2. Buyer power<br /> 3.3.1.3. Substitution threat<br /> 3.3.1.4. Threat of new entrant<br /> 3.3.1.5. Competitive rivalry<br /> 3.3.2. PESTEL Analysis<br /> 3.3.2.1. Political landscape<br /> 3.3.2.2. Technological landscape<br /> 3.3.2.3. Economic landscape<br /> 3.3.3. Pipeline Analysis </p> <p> <span style="font-weight:bold;">Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis</span> <br /> 4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard<br /> 4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis<br /> 4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue<br /> 4.4. Myeloblastic Leukemia<br /> 4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.5. Myelomonocytic Leukemia<br /> 4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.6. Promyelocytic Leukemia<br /> 4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.7. Monocytic Leukemia<br /> 4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.8. Other Diseases<br /> 4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis</span> <br /> 5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard<br /> 5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis<br /> 5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)<br /> 5.4. Chemotherapy<br /> 5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.2. Anti-metabolites<br /> 5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.3. Alkylating agents<br /> 5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.4. Anthracycline drugs<br /> 5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.5. Others<br /> 5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5. Targeted Therapy<br /> 5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2. FLT3 inhibitors<br /> 5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.1. Rydapt<br /> 5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.2. Vanflyta<br /> 5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.3. Xospata<br /> 5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3. IDH inhibitors<br /> 5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.1. Tibsovo<br /> 5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.2. Rezlidhia<br /> 5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.3. Idhifa<br /> 5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.4. Mylotarg<br /> 5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5. BCL-2 inhibitor<br /> 5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5.1.1. Venclexta<br /> 5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6. Hedgehog pathway inhibitor<br /> 5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6.1.1. Daurismo<br /> 5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6. Immunotherapy<br /> 5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.1. Bispecific antibodies<br /> 5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.2. Antibody-drug conjugates<br /> 5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.4. Immune checkpoint inhibitors<br /> 5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy<br /> 5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.7. Other Treatments<br /> 5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis</span> <br /> 6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard<br /> 6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis<br /> 6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)<br /> 6.4. Parenteral<br /> 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)<br /> 6.5. Oral<br /> 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis</span> <br /> 7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard<br /> 7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis<br /> 7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)<br /> 7.4. Hospital and Clinics<br /> 7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.5. Specialty Centers<br /> 7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.6. Homecare Setting<br /> 7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration</span> <br /> 8.1. Regional Dashboard<br /> 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:<br /> 8.3. North America<br /> 8.3.1. U.S.<br /> 8.3.1.1. Key country dynamics<br /> 8.3.1.2. Regulatory framework/ reimbursement structure<br /> 8.3.1.3. Competitive scenario<br /> 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.2. Canada<br /> 8.3.2.1. Key country dynamics<br /> 8.3.2.2. Regulatory framework/ reimbursement structure<br /> 8.3.2.3. Competitive scenario<br /> 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.3. Mexico<br /> 8.3.3.1. Key country dynamics<br /> 8.3.3.2. Regulatory framework/ reimbursement structure<br /> 8.3.3.3. Competitive scenario<br /> 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4. Europe<br /> 8.4.1. UK<br /> 8.4.1.1. Key country dynamics<br /> 8.4.1.2. Regulatory framework/ reimbursement structure<br /> 8.4.1.3. Competitive scenario<br /> 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.2. Germany<br /> 8.4.2.1. Key country dynamics<br /> 8.4.2.2. Regulatory framework/ reimbursement structure<br /> 8.4.2.3. Competitive scenario<br /> 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.3. France<br /> 8.4.3.1. Key country dynamics<br /> 8.4.3.2. Regulatory framework/ reimbursement structure<br /> 8.4.3.3. Competitive scenario<br /> 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.4. Italy<br /> 8.4.4.1. Key country dynamics<br /> 8.4.4.2. Regulatory framework/ reimbursement structure<br /> 8.4.4.3. Competitive scenario<br /> 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.5. Spain<br /> 8.4.5.1. Key country dynamics<br /> 8.4.5.2. Regulatory framework/ reimbursement structure<br /> 8.4.5.3. Competitive scenario<br /> 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.6. Norway<br /> 8.4.6.1. Key country dynamics<br /> 8.4.6.2. Regulatory framework/ reimbursement structure<br /> 8.4.6.3. Competitive scenario<br /> 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.7. Sweden<br /> 8.4.7.1. Key country dynamics<br /> 8.4.7.2. Regulatory framework/ reimbursement structure<br /> 8.4.7.3. Competitive scenario<br /> 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.8. Denmark<br /> 8.4.8.1. Key country dynamics<br /> 8.4.8.2. Regulatory framework/ reimbursement structure<br /> 8.4.8.3. Competitive scenario<br /> 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5. Asia Pacific<br /> 8.5.1. Japan<br /> 8.5.1.1. Key country dynamics<br /> 8.5.1.2. Regulatory framework/ reimbursement structure<br /> 8.5.1.3. Competitive scenario<br /> 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.2. China<br /> 8.5.2.1. Key country dynamics<br /> 8.5.2.2. Regulatory framework/ reimbursement structure<br /> 8.5.2.3. Competitive scenario<br /> 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.3. India<br /> 8.5.3.1. Key country dynamics<br /> 8.5.3.2. Regulatory framework/ reimbursement structure<br /> 8.5.3.3. Competitive scenario<br /> 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.4. Australia<br /> 8.5.4.1. Key country dynamics<br /> 8.5.4.2. Regulatory framework/ reimbursement structure<br /> 8.5.4.3. Competitive scenario<br /> 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.5. South Korea<br /> 8.5.5.1. Key country dynamics<br /> 8.5.5.2. Regulatory framework/ reimbursement structure<br /> 8.5.5.3. Competitive scenario<br /> 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.6. Thailand<br /> 8.5.6.1. Key country dynamics<br /> 8.5.6.2. Regulatory framework/ reimbursement structure<br /> 8.5.6.3. Competitive scenario<br /> 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6. Latin America<br /> 8.6.1. Brazil<br /> 8.6.1.1. Key country dynamics<br /> 8.6.1.2. Regulatory framework/ reimbursement structure<br /> 8.6.1.3. Competitive scenario<br /> 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6.2. Argentina<br /> 8.6.2.1. Key country dynamics<br /> 8.6.2.2. Regulatory framework/ reimbursement structure<br /> 8.6.2.3. Competitive scenario<br /> 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7. MEA<br /> 8.7.1. South Africa<br /> 8.7.1.1. Key country dynamics<br /> 8.7.1.2. Regulatory framework/ reimbursement structure<br /> 8.7.1.3. Competitive scenario<br /> 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.2. Saudi Arabia<br /> 8.7.2.1. Key country dynamics<br /> 8.7.2.2. Regulatory framework/ reimbursement structure<br /> 8.7.2.3. Competitive scenario<br /> 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.3. UAE<br /> 8.7.3.1. Key country dynamics<br /> 8.7.3.2. Regulatory framework/ reimbursement structure<br /> 8.7.3.3. Competitive scenario<br /> 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.4. Kuwait<br /> 8.7.4.1. Key country dynamics<br /> 8.7.4.2. Regulatory framework/ reimbursement structure<br /> 8.7.4.3. Competitive scenario<br /> 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 9. Competitive Landscape</span> <br /> 9.1. Company/Competition Categorization<br /> 9.2. Vendor Landscape<br /> 9.2.1. List of key distributors and channel partners<br /> 9.2.2. Key customers<br /> 9.2.3. Key company market share analysis, 2023<br /> 9.2.4. Astellas Pharma Inc.<br /> 9.2.4.1. Company overview<br /> 9.2.4.2. Financial performance<br /> 9.2.4.3. Product benchmarking<br /> 9.2.4.4. Strategic initiatives<br /> 9.2.5. Bristol Myers Squibb Company<br /> 9.2.5.1. Company overview<br /> 9.2.5.2. Financial performance<br /> 9.2.5.3. Product benchmarking<br /> 9.2.5.4. Strategic initiatives<br /> 9.2.6. Celgene Corporation<br /> 9.2.6.1. Company overview<br /> 9.2.6.2. Financial performance<br /> 9.2.6.3. Product benchmarking<br /> 9.2.6.4. Strategic initiatives<br /> 9.2.7. Daiichi Sankyo Company, Limited<br /> 9.2.7.1. Company overview<br /> 9.2.7.2. Financial performance<br /> 9.2.7.3. Product benchmarking<br /> 9.2.7.4. Strategic initiatives<br /> 9.2.8. Jazz Pharmaceuticals, plc<br /> 9.2.8.1. Company overview<br /> 9.2.8.2. Financial performance<br /> 9.2.8.3. Product benchmarking<br /> 9.2.8.4. Strategic initiatives<br /> 9.2.9. Novartis AG<br /> 9.2.9.1. Company overview<br /> 9.2.9.2. Financial performance<br /> 9.2.9.3. Product benchmarking<br /> 9.2.9.4. Strategic initiatives<br /> 9.2.10. Otsuka Pharmaceuticals Co., Ltd.<br /> 9.2.10.1. Company overview<br /> 9.2.10.2. Financial performance<br /> 9.2.10.3. Product benchmarking<br /> 9.2.10.4. Strategic initiatives<br /> 9.2.11. Pfizer, Inc.<br /> 9.2.11.1. Company overview<br /> 9.2.11.2. Financial performance<br /> 9.2.11.3. Product benchmarking<br /> 9.2.11.4. Strategic initiatives<br /> 9.2.12. Rigel Pharmaceuticals, Inc.<br /> 9.2.12.1. Company overview<br /> 9.2.12.2. Financial performance<br /> 9.2.12.3. Product benchmarking<br /> 9.2.12.4. Strategic initiatives<br /> 9.2.13. Merck & Co., Inc.<br /> 9.2.13.1. Company overview<br /> 9.2.13.2. Financial performance<br /> 9.2.13.3. Product benchmarking<br /> 9.2.13.4. Strategic initiatives<br /> 9.2.14. Sanofi<br /> 9.2.14.1. Company overview<br /> 9.2.14.2. Financial performance<br /> 9.2.14.3. Product<br /> 9.2.14.4. Benchmarking<br /> 9.2.14.5. Strategic initiatives </p> <p> <span style="font-weight:bold;">List of Tables</span> <br /> Table 1 List of abbreviation<br /> Table 2 North America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 3 North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 4 North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 5 North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 6 North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 7 U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 8 U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 9 U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 10 U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 11 Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 12 Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 13 Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 14 Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 15 Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 16 Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 17 Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 18 Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 19 Europe acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 20 Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 21 Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 22 Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 23 Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 24 Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 25 Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 26 Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 27 Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 28 UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 29 UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 30 UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 31 UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 32 France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 33 France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 34 France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 35 France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 36 Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 37 Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 38 Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 39 Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 40 Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 41 Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 42 Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 43 Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 44 Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 45 Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 46 Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 47 Denmark Acute Myeloid Leukemia Treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 48 Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 49 Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 50 Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 51 Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 52 Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 53 Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 54 Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 55 Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 56 Asia Pacific acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 57 Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 58 Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 59 Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 60 Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 61 China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 62 China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 63 China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 64 China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 65 Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 66 Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 67 Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 68 Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 69 India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 70 India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 71 India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 72 India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 73 South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 74 South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 75 South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 76 South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 77 Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 78 Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 79 Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 80 Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 81 Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 82 Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 83 Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 84 Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 85 Latin America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 86 Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 87 Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 88 Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 89 Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 90 Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 91 Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 92 Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 93 Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 94 Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 95 Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 96 Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 97 Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 98 MEA acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 99 MEA acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 100 MEA acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 101 MEA acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 102 MEA acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 103 South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 104 South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 105 South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 106 South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 107 Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 108 Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 109 Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 110 Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 111 UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 112 UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 113 UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 114 UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 115 Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 116 Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 117 Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 118 Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million) </p> <p> <span style="font-weight:bold;">List of Figures</span> <br /> Fig. 1 Market research process<br /> Fig. 2 Data triangulation techniques<br /> Fig. 3 Primary research pattern<br /> Fig. 4 Primary interviews in North America<br /> Fig. 5 Primary interviews in Europe<br /> Fig. 6 Primary interviews in APAC<br /> Fig. 7 Primary interviews in Latin America<br /> Fig. 8 Primary interviews in MEA<br /> Fig. 9 Market research approaches<br /> Fig. 10 Value-chain-based sizing & forecasting<br /> Fig. 11 QFD modeling for market share assessment<br /> Fig. 12 Market formulation & validation<br /> Fig. 13 Acute myeloid leukemia treatment market: market outlook<br /> Fig. 14 Acute myeloid leukemia treatment competitive insights<br /> Fig. 15 Parent market outlook<br /> Fig. 16 Related/ancillary market outlook<br /> Fig. 17 Acute myeloid leukemia treatment market driver impact<br /> Fig. 18 Acute myeloid leukemia treatment market restraint impact<br /> Fig. 19 Acute myeloid leukemia treatment market: disease movement analysis<br /> Fig. 20 Acute myeloid leukemia treatment market: disease outlook and key takeaways<br /> Fig. 21 Myeloblastic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 22 Myelomonocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 23 Promyelocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 25 Monocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 26 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 27 Acute myeloid leukemia treatment market: Treatment movement analysis<br /> Fig. 28 Acute myeloid leukemia treatment market: Treatment outlook and key takeaways<br /> Fig. 29 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 30 Anti-metabolites market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 31 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 32 Anthracycline drugs market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 34 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 35 FLT3 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 36 Rydapt market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 37 Vanflyta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 38 Xospata market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 39 IDH inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 40 Tibsovo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 41 Rezlidhia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 42 Idhifa market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 43 Mylotarg market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 44 BCL-2 inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 45 Venclexta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 46 Hedgehog pathway inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 47 Daurismo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 48 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 49 Bispecific antibodies market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 50 Antibody-drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 51 Immune checkpoint inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 52 Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 53 Other treatments market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 54 Acute myeloid leukemia treatment market: Route of administration movement analysis<br /> Fig. 55 Acute myeloid leukemia treatment market: Route of administration outlook and key takeaways<br /> Fig. 56 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 57 Oral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 58 Acute myeloid leukemia treatment market: End Use movement analysis<br /> Fig. 59 Acute myeloid leukemia treatment market: End Use outlook and key takeaways<br /> Fig. 60 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 61 Specialty centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 62 Homecare setting market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 63 Ambulatory care centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 64 Global acute myeloid leukemia treatment market: Regional movement analysis<br /> Fig. 65 Global acute myeloid leukemia treatment market: Regional outlook and key takeaways<br /> Fig. 66 Global acute myeloid leukemia treatment market share and leading players<br /> Fig. 67 North America, by country<br /> Fig. 68 North America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 69 U.S. key country dynamics<br /> Fig. 70 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 71 Canada key country dynamics<br /> Fig. 72 Canada market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 73 Mexico key country dynamics<br /> Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 75 Europe market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 76 UK key country dynamics<br /> Fig. 77 UK market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 78 Germany key country dynamics<br /> Fig. 79 Germany market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 80 France key country dynamics<br /> Fig. 81 France market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 82 Italy key country dynamics<br /> Fig. 83 Italy market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 84 Spain key country dynamics<br /> Fig. 85 Spain market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 86 Denmark key country dynamics<br /> Fig. 87 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 88 Sweden key country dynamics<br /> Fig. 89 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 90 Norway key country dynamics<br /> Fig. 91 Norway market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 93 China key country dynamics<br /> Fig. 94 China market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 95 Japan key country dynamics<br /> Fig. 96 Japan market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 97 India key country dynamics<br /> Fig. 98 India market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 99 Thailand key country dynamics<br /> Fig. 100 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 101 South Korea key country dynamics<br /> Fig. 102 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 103 Australia key country dynamics<br /> Fig. 104 Australia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 105 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 106 Brazil key country dynamics<br /> Fig. 107 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 108 Argentina key country dynamics<br /> Fig. 109 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 110 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 111 South Africa key country dynamics<br /> Fig. 112 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 113 Saudi Arabia key country dynamics<br /> Fig. 114 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 115 UAE key country dynamics<br /> Fig. 116 UAE market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 117 Kuwait key country dynamics<br /> Fig. 118 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 119 Market share of key market players- acute myeloid leukemia treatment market </p> ', 'update_date' => '2024-08-19 14:22:18' ) ), 'report_pdf' => array(), 'report_base' => array( 'id' => '39052', 'pj_code' => '999999', 'title_main' => 'æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030', 'title_volume' => '', 'title_volumetitle' => '', 'charge_person' => '37', 'subtitle' => 'Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030', 'keyword1' => '急性骨髄性白血病治療薬', 'keyword2' => '予測', 'keyword3' => '', 'keyword4' => '', 'keyword5' => '', 'summary1' => '', 'summary2' => '', 'summary3' => '', 'language' => '2', 'disp_status' => '1', 'publish_status' => '1', 'publish_date' => '2024-07-01', 'publish_date_ymdsp' => true, 'publish_check' => null, 'price_reserve' => '0', 'price_reserve2' => '0', 'price_reserve3' => '0', 'price_reserve4' => '0', 'price_reserve5' => '0', 'license_reserve' => '', 'license_reserve2' => '', 'license_reserve3' => '', 'license_reserve4' => '', 'license_reserve5' => '', 'price' => '5950', 'price2' => '6950', 'price3' => '8950', 'price4' => '0', 'price5' => '0', 'price6' => '0', 'price7' => '0', 'price8' => '0', 'license' => 'Individual', 'license2' => 'Team', 'license3' => 'Enterprise', 'license4' => '', 'license5' => '', 'license6' => '', 'license7' => '', 'license8' => '', 'unit_e' => null, 'unit' => 'USD', 'style_format' => 'PDF', 'about_flag' => '0', 'style_page' => '175', 'publishing_office' => 'Grand View Research Inc.', 'note' => '※ã”請求ã¯ã€ãŠç”³è¾¼æ—¥ã®TTSレートã§å††æ›ç®—ã—ã€æ¶ˆè²»ç¨Žã‚’åŠ ãˆãŸé‡‘é¡ã«ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯ã€è‹±æ–‡ã§ã™ã€‚PDF(é›»å媒体)ã§ã®ç´å“ã¨ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯å–り寄ã›ã¨ãªã‚Šã¾ã™ã®ã§ã€ç”³ã—è¾¼ã¿ã‹ã‚‰ãŠå±Šã‘ã¾ã§ã€å¤šå°‘時間ãŒæŽ›ã‹ã‚‹å ´åˆãŒã”ã–ã„ã¾ã™ã€‚', 'color' => '2', 'scolor' => null, 'outline' => '<p> <span style="font-weight:bold;">急性骨髄性白血病治療ã®å¸‚å ´è¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆï¼šç–¾æ‚£åˆ¥ (骨髄芽çƒæ€§ç™½è¡€ç—…ã€éª¨é«„å˜çƒæ€§ç™½è¡€ç—…)ã€æ²»ç™‚別 (化å¦ç™‚法)ã€æŠ•ä¸ŽçµŒè·¯åˆ¥ã€æœ€çµ‚用途別ã€åœ°åŸŸåˆ¥ã€ã‚»ã‚°ãƒ¡ãƒ³ãƒˆåˆ¥äºˆæ¸¬ã€2024-2030 </span> </p> <p> <span style="font-weight:bold;">å¸‚å ´è¦æ¨¡ã¨å‹•å‘</span> </p> <p> 世界ã®æ€¥æ€§éª¨é«„性白血病治療薬ã®å¸‚å ´è¦æ¨¡ã¯ã€2023å¹´ã«31å„„8000万ドルã¨æŽ¨å®šã•ã‚Œã€2024å¹´ã‹ã‚‰2030å¹´ã«ã‹ã‘ã¦10.44%ã®CAGRã§æˆé•·ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚高度ãªæ²»ç™‚è–¬ã«å¯¾ã™ã‚‹ãƒ‹ãƒ¼ã‚ºã®é«˜ã¾ã‚Šã‚‚ã€ã“ã®å¸‚å ´ã«å¤§ããªå½±éŸ¿åŠ›ã‚’æŒã¤æŽ¨é€²è¦å› ã§ã™ã€‚急性骨髄性白血病治療薬ã®ç™ºç”ŸçŽ‡ã®ä¸Šæ˜‡ã¯ã€éºä¼å変異ã€ä¸å¥åº·ãªç”Ÿæ´»ç¿’æ…£ã€ãƒ™ãƒ³ã‚¼ãƒ³ãªã©ã®æœ‰å®³åŒ–å¦ç‰©è³ªã¸ã®ç¶™ç¶šçš„ãªæ›éœ²ã€æ”¾å°„線被ã°ããªã©ã®è¦å› ã«èµ·å› ã—ã¦ã„ã¾ã™ã€‚ã•ã‚‰ã«ã€é«˜é½¢è€…人å£ã®å¢—åŠ ã¨æº€ãŸã•ã‚Œã¦ã„ãªã„医療ニーズã®é«˜ã¾ã‚ŠãŒã€å¸‚å ´ã®æˆé•·ã‚’ã•ã‚‰ã«å¾ŒæŠ¼ã—ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚2024å¹´ã«ç±³å›½ãŒã‚“å”会ãŒç™ºè¡¨ã—ãŸæŽ¨å®šã«ã‚ˆã‚‹ã¨ã€ç´„20,800人ãŒæ€¥æ€§éª¨é«„性白血病ã¨è¨ºæ–ã•ã‚Œã¾ã—ãŸã€‚ </p> ', 'memo' => 'https://www.grandviewresearch.com/industry-analysis/acute-myeloid-leukemia-therapeutics-market', 'catalog_copy' => '', 'pamphlet_pdf' => '0', 's_upload' => null, 'i_upload' => '1', 'update_flag' => null, 'update_date' => '2024-08-19 14:21:48', 'regist_date' => '0000-00-00 00:00:00' ), 'session_carts' => array(), 'id' => null, 'checked_reports' => array(), 'category_list' => array( (int) 1 => array( (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ), (int) 6 => array( [maximum depth reached] ), (int) 7 => array( [maximum depth reached] ), (int) 8 => array( [maximum depth reached] ), (int) 9 => array( [maximum depth reached] ) ), (int) 2 => array( (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ), (int) 6 => array( [maximum depth reached] ), (int) 7 => array( [maximum depth reached] ), (int) 8 => array( [maximum depth reached] ), (int) 9 => array( [maximum depth reached] ), (int) 10 => array( [maximum depth reached] ) ), (int) 3 => array( (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ), (int) 6 => array( [maximum depth reached] ) ), (int) 4 => array( (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ) ), (int) 5 => array( (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ), (int) 6 => array( [maximum depth reached] ), (int) 7 => array( [maximum depth reached] ) ), (int) 6 => array( (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ) ) ), 'category_sub_list' => array( (int) 0 => array( 'CategoryMain' => array( [maximum depth reached] ), 'CategorySub' => array( [maximum depth reached] ) ), (int) 1 => array( 'CategoryMain' => array( [maximum depth reached] ), 'CategorySub' => array( [maximum depth reached] ) ), (int) 2 => array( 'CategoryMain' => array( [maximum depth reached] ), 'CategorySub' => array( [maximum depth reached] ) ), (int) 3 => array( 'CategoryMain' => array( [maximum depth reached] ), 'CategorySub' => array( [maximum depth reached] ) ), (int) 4 => array( 'CategoryMain' => array( [maximum depth reached] ), 'CategorySub' => array( [maximum depth reached] ) ), (int) 5 => array( 'CategoryMain' => array( [maximum depth reached] ), 'CategorySub' => array( [maximum depth reached] ) ) ), 'category_main_list' => array( (int) 1 => 'エレクトãƒãƒ‹ã‚¯ã‚¹ãƒ»IT', (int) 2 => 'メディカル・ãƒã‚¤ã‚ª', (int) 3 => 'ウエルãƒã‚¹', (int) 4 => '医療IT', (int) 5 => 'エãƒãƒ«ã‚®ãƒ¼ãƒ»ç’°å¢ƒ', (int) 6 => 'ビジãƒã‚¹ä¸€èˆ¬ãƒ»ãã®ä»–' ), 'tax' => '0.1', 'content_for_layout' => ' <style type="text/css"> @media screen and (min-width: 980px) { .report_patarn_license{ display:flex; } } .report_discription p { margin-bottom:10px; } .report_discription .details { margin-bottom:20px; } .report_discription .details h4 { padding:10px 0px; font-size:18px; border-top:1px solid #666; border-bottom:1px solid #666; margin:0px 0px 10px 0px; } .report_discription .details table { border-collapse:collapse; border-spacing:0px; width:100%; } .report_discription .details table th { background-color: #006dc3; background-color:lightblue; } .report_discription .details table th, .report_discription .details table td { /*border:1px solid #999; padding:5px;*/ /*border:none;*/ } /* table th,table td{ border:1px solid #999; padding:5px; } */ .report_discription .details .mu_table th, .report_discription .details .mu_table td { /*border:1px solid #999; padding:5px;*/ border:none; } .tooltip_favorite { position:absolute; left :800px; margin : 5px; display: inline-block; text-align: center; min-width: 120px; max-width: 100%; color: #006dc3; font-size: 16px; background: #fff; border : solid 1px; border-color : #005bb8; border-radius: 30px; } .sample_report{ border: none; background-color: transparent; font-size: 15px; color:#299cbd; cursor:pointer } .license_table{ empty-cells: show; border-right:1px solid #ccc; font-size:16px; margin:5px 5px; } .license_td{ text-align:center; vertical-align: middle; color:#fff; border-bottom:1px solid #ccc; background-color:#006dc3; border-bottom:1px solid #ccc; border-left:1px solid #ccc; border:1; height:50px; width:200px; font-size:15px; } .price_td{ text-align:center; vertical-align: middle; background-color:#fff; border-bottom:1px solid #ccc; border-right:1px solid #ccc; border:1; height:50px; width:200px; font-size:17px; } .format_td{ text-align:center; vertical-align: middle; background-color:#006dc3; border-bottom:1px solid #ccc; border-right:1px solid #ccc; border:1; height:50px; width:200px; font-size:17px; color:white; } .btn_cart_div{ display:flex; text-align:center; -webkit-justify-content: center; margin:20px 0px; padding:0px 50px; } </style> <div class="breadcrumb clearfix"> <ul> <li class="home"><a href="/">ホーム</a></li> <li><a href="/categories/index/?m_id=2">メディカル・ãƒã‚¤ã‚ª</a></li> <li>æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030</li> </ul> </div><!--/breadcrumb--> <div class="detail_main"> <form action="/categories/detail/39052?url=categories%2Fdetail%2F39052" id="detailForm" method="post" accept-charset="utf-8"><div style="display:none;"><input type="hidden" name="_method" value="POST"/></div> <div class="detail_mainIn"> <div class="detail_main_box"> <p class="report_number">レãƒãƒ¼ãƒˆãƒŠãƒ³ãƒãƒ¼ã€€0000039052</p> <div class="category"><a href="/categories/index/?m_id=2&s_id=1">医薬å“原料・製剤</a></div> <div class="category"><a href="/categories/index/?m_id=2&s_id=3">ç–¾ç—…åˆ¥æ²»ç™‚ãƒ»é ˜åŸŸåˆ¥æ²»ç™‚</a></div> <h3>æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030</h3> <p class="company">Grand View Research Inc.</p> <p class="subTitle"></p> <p class="subTitle"></p> <p class="subTitle">Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030</p> <div class="data"> <p><span>発刊日</span> 2024/07 <p><span>言語</span>英語</p> <p><span>体è£</span>PDF/175ページ</p> </div> </div><!--/detail_main_box--> <div class="detail_cart_area"> <div class="report_patarn clearfix"> <p class="report_patarnIn">ライセンス/ä¾¡æ ¼<span>175ページ</span></p> <p class="report_sub_number"> 0000039052 </p> </div> <div class="report_patarn_license clearfix"> <!--<p class="license_text"> æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030<br> Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030 </p>--> <div class= "cart_div"> <table border=1 class="license_table"><!--<p class="license_price">--> <tbody> <!--<tr> <td class="license_td"> Individual </td> <td class="license_td"> Team </td> <td class="license_td"> Enterprise </td> </tr>--> <tr> <th class="license_td"> Individual </th> <td class="price_td"> <input type="radio" name="data[ReportBase][license]" class="license_radio" id="license" value="1" checked/> <label for="license">5,950USD</label><br> </td> </tr> <tr> <th class="license_td"> Team </th> <td class="price_td"> <input type="radio" name="data[ReportBase][license]" class="license_radio" id="license2" value="2" /> <label for="license2">6,950USD</label><br> </td> </tr> <tr> <th class="license_td"> Enterprise </th> <td class="price_td"> <input type="radio" name="data[ReportBase][license]" class="license_radio" id="license3" value="3" /> <label for="license3">8,950USD</label><br> </td> </tr> </tr> </tr> </tr> </tr> </tr> </tbody> </table><!--</p>--> </div> <div class="btn_cart_div"> <div class="btn_cart"> <input type="hidden" name="data[carts]" value="39052" id="carts"/> <button name="carts_add" id="carts_add">カートã¸</button> </div><!--/btn_cart--> <div class="btn_cart"> <input type="hidden" name="data[carts]" value="39052" id="carts"/> <button name="carts_now" id="carts_now">今ã™ã購入</button> </div><!--/btn_cart--> </div><!--/cart_div--> </div> </div><!--/detail_cart_area--> <p>※ã”請求ã¯ã€ãŠç”³è¾¼æ—¥ã®TTSレートã§å††æ›ç®—ã—ã€æ¶ˆè²»ç¨Žã‚’åŠ ãˆãŸé‡‘é¡ã«ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯ã€è‹±æ–‡ã§ã™ã€‚PDF(é›»å媒体)ã§ã®ç´å“ã¨ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯å–り寄ã›ã¨ãªã‚Šã¾ã™ã®ã§ã€ç”³ã—è¾¼ã¿ã‹ã‚‰ãŠå±Šã‘ã¾ã§ã€å¤šå°‘時間ãŒæŽ›ã‹ã‚‹å ´åˆãŒã”ã–ã„ã¾ã™ã€‚</p> <div class="btn_report_set"> <div class="btn01" style="margin:0px auto;"> <!--<button type="submit" class="contact" value="product_id">商å“ã‚’å•ã„åˆã‚ã›ã‚‹</button>--> <a href="https://www.spi-information.com/contacts/report_contact?report=39052&sample=0">ãŠå•ã„åˆã‚ã›</a> </div> <div class="btn01" style="margin:0px auto;"><a href="https://www.spi-information.com/contacts/report_contact?report=39052&sample=1">サンプルä¾é ¼</a></div> <button class="btn-form-cart" name="estimate" value="1">見ç©æ›¸ä½œæˆ</button> </div><!--/btn_report_set--> <div class="sample_box"> <p>無料サンプル</p> <ul> <li>サンプルã¯ãŠå•ã„åˆã‚ã›ãã ã•ã„。</li> </ul> </div><!--/sample_box--> <div class="report_discription"> <h3>レãƒãƒ¼ãƒˆæ¦‚è¦</h3> <p> <span style="font-weight:bold;">急性骨髄性白血病治療ã®å¸‚å ´è¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆï¼šç–¾æ‚£åˆ¥ (骨髄芽çƒæ€§ç™½è¡€ç—…ã€éª¨é«„å˜çƒæ€§ç™½è¡€ç—…)ã€æ²»ç™‚別 (化å¦ç™‚法)ã€æŠ•ä¸ŽçµŒè·¯åˆ¥ã€æœ€çµ‚用途別ã€åœ°åŸŸåˆ¥ã€ã‚»ã‚°ãƒ¡ãƒ³ãƒˆåˆ¥äºˆæ¸¬ã€2024-2030 </span> </p> <p> <span style="font-weight:bold;">å¸‚å ´è¦æ¨¡ã¨å‹•å‘</span> </p> <p> 世界ã®æ€¥æ€§éª¨é«„性白血病治療薬ã®å¸‚å ´è¦æ¨¡ã¯ã€2023å¹´ã«31å„„8000万ドルã¨æŽ¨å®šã•ã‚Œã€2024å¹´ã‹ã‚‰2030å¹´ã«ã‹ã‘ã¦10.44%ã®CAGRã§æˆé•·ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚高度ãªæ²»ç™‚è–¬ã«å¯¾ã™ã‚‹ãƒ‹ãƒ¼ã‚ºã®é«˜ã¾ã‚Šã‚‚ã€ã“ã®å¸‚å ´ã«å¤§ããªå½±éŸ¿åŠ›ã‚’æŒã¤æŽ¨é€²è¦å› ã§ã™ã€‚急性骨髄性白血病治療薬ã®ç™ºç”ŸçŽ‡ã®ä¸Šæ˜‡ã¯ã€éºä¼å変異ã€ä¸å¥åº·ãªç”Ÿæ´»ç¿’æ…£ã€ãƒ™ãƒ³ã‚¼ãƒ³ãªã©ã®æœ‰å®³åŒ–å¦ç‰©è³ªã¸ã®ç¶™ç¶šçš„ãªæ›éœ²ã€æ”¾å°„線被ã°ããªã©ã®è¦å› ã«èµ·å› ã—ã¦ã„ã¾ã™ã€‚ã•ã‚‰ã«ã€é«˜é½¢è€…人å£ã®å¢—åŠ ã¨æº€ãŸã•ã‚Œã¦ã„ãªã„医療ニーズã®é«˜ã¾ã‚ŠãŒã€å¸‚å ´ã®æˆé•·ã‚’ã•ã‚‰ã«å¾ŒæŠ¼ã—ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚2024å¹´ã«ç±³å›½ãŒã‚“å”会ãŒç™ºè¡¨ã—ãŸæŽ¨å®šã«ã‚ˆã‚‹ã¨ã€ç´„20,800人ãŒæ€¥æ€§éª¨é«„性白血病ã¨è¨ºæ–ã•ã‚Œã¾ã—ãŸã€‚ </p> <h3>レãƒãƒ¼ãƒˆè©³ç´°</h3> <div class="details"> <h4>目次</h4> <p> <span style="font-weight:bold;">Table of Contents</span> </p> <p> <span style="font-weight:bold;">Chapter 1. Methodology and Scope</span> <br /> 1.1. Market Segmentation & Scope<br /> 1.2. Segment Definitions<br /> 1.2.1. Disease<br /> 1.2.2. Treatment<br /> 1.2.3. Route of Administration<br /> 1.2.4. End Use<br /> 1.2.5. Regional scope<br /> 1.2.6. Estimates and forecasts timeline<br /> 1.3. Research Methodology<br /> 1.4. Information Procurement<br /> 1.4.1. Purchased database<br /> 1.4.2. GVR’s internal database<br /> 1.4.3. Secondary sources<br /> 1.4.4. Primary research<br /> 1.4.5. Details of primary research<br /> 1.4.5.1. Data for primary interviews in North America<br /> 1.4.5.2. Data for primary interviews in Europe<br /> 1.4.5.3. Data for primary interviews in Asia Pacific<br /> 1.4.5.4. Data for primary interviews in Latin America<br /> 1.4.5.5. Data for Primary interviews in MEA<br /> 1.5. Information or Data Analysis<br /> 1.5.1. Data analysis models<br /> 1.6. Market Formulation & Validation<br /> 1.7. Model Details<br /> 1.7.1. Commodity flow analysis (Model 1)<br /> 1.7.2. Approach 1: Commodity flow approach<br /> 1.7.3. Volume price analysis (Model 2)<br /> 1.7.4. Approach 2: Volume price analysis<br /> 1.8. List of Secondary Sources<br /> 1.9. List of Primary Sources<br /> 1.10. Objectives </p> <p> <span style="font-weight:bold;">Chapter 2. Executive Summary</span> <br /> 2.1. Market Outlook<br /> 2.2. Segment Outlook<br /> 2.2.1. Disease outlook<br /> 2.2.2. Treatment outlook<br /> 2.2.3. Route of Administration outlook<br /> 2.2.4. End Use outlook<br /> 2.2.5. Regional outlook<br /> 2.3. Competitive Insights </p> <p> <span style="font-weight:bold;">Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope</span> <br /> 3.1. Market Lineage Outlook<br /> 3.1.1. Parent market outlook<br /> 3.1.2. Related/ancillary market outlook<br /> 3.2. Market Dynamics<br /> 3.2.1. Market driver analysis<br /> 3.2.1.1. Increasing prevalence of acute myeloid leukemia<br /> 3.2.1.2. Advancements in diagnostic techniques<br /> 3.2.1.3. Growing investments in R&D techniques<br /> 3.2.2. Market restraint analysis<br /> 3.2.2.1. High cost of treatment<br /> 3.2.2.2. Limited treatment options<br /> 3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools<br /> 3.3.1. Industry Analysis - Porter’s Five Forces<br /> 3.3.1.1. Supplier power<br /> 3.3.1.2. Buyer power<br /> 3.3.1.3. Substitution threat<br /> 3.3.1.4. Threat of new entrant<br /> 3.3.1.5. Competitive rivalry<br /> 3.3.2. PESTEL Analysis<br /> 3.3.2.1. Political landscape<br /> 3.3.2.2. Technological landscape<br /> 3.3.2.3. Economic landscape<br /> 3.3.3. Pipeline Analysis </p> <p> <span style="font-weight:bold;">Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis</span> <br /> 4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard<br /> 4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis<br /> 4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue<br /> 4.4. Myeloblastic Leukemia<br /> 4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.5. Myelomonocytic Leukemia<br /> 4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.6. Promyelocytic Leukemia<br /> 4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.7. Monocytic Leukemia<br /> 4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.8. Other Diseases<br /> 4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis</span> <br /> 5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard<br /> 5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis<br /> 5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)<br /> 5.4. Chemotherapy<br /> 5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.2. Anti-metabolites<br /> 5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.3. Alkylating agents<br /> 5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.4. Anthracycline drugs<br /> 5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.5. Others<br /> 5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5. Targeted Therapy<br /> 5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2. FLT3 inhibitors<br /> 5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.1. Rydapt<br /> 5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.2. Vanflyta<br /> 5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.3. Xospata<br /> 5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3. IDH inhibitors<br /> 5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.1. Tibsovo<br /> 5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.2. Rezlidhia<br /> 5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.3. Idhifa<br /> 5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.4. Mylotarg<br /> 5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5. BCL-2 inhibitor<br /> 5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5.1.1. Venclexta<br /> 5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6. Hedgehog pathway inhibitor<br /> 5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6.1.1. Daurismo<br /> 5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6. Immunotherapy<br /> 5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.1. Bispecific antibodies<br /> 5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.2. Antibody-drug conjugates<br /> 5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.4. Immune checkpoint inhibitors<br /> 5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy<br /> 5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.7. Other Treatments<br /> 5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis</span> <br /> 6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard<br /> 6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis<br /> 6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)<br /> 6.4. Parenteral<br /> 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)<br /> 6.5. Oral<br /> 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis</span> <br /> 7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard<br /> 7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis<br /> 7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)<br /> 7.4. Hospital and Clinics<br /> 7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.5. Specialty Centers<br /> 7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.6. Homecare Setting<br /> 7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration</span> <br /> 8.1. Regional Dashboard<br /> 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:<br /> 8.3. North America<br /> 8.3.1. U.S.<br /> 8.3.1.1. Key country dynamics<br /> 8.3.1.2. Regulatory framework/ reimbursement structure<br /> 8.3.1.3. Competitive scenario<br /> 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.2. Canada<br /> 8.3.2.1. Key country dynamics<br /> 8.3.2.2. Regulatory framework/ reimbursement structure<br /> 8.3.2.3. Competitive scenario<br /> 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.3. Mexico<br /> 8.3.3.1. Key country dynamics<br /> 8.3.3.2. Regulatory framework/ reimbursement structure<br /> 8.3.3.3. Competitive scenario<br /> 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4. Europe<br /> 8.4.1. UK<br /> 8.4.1.1. Key country dynamics<br /> 8.4.1.2. Regulatory framework/ reimbursement structure<br /> 8.4.1.3. Competitive scenario<br /> 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.2. Germany<br /> 8.4.2.1. Key country dynamics<br /> 8.4.2.2. Regulatory framework/ reimbursement structure<br /> 8.4.2.3. Competitive scenario<br /> 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.3. France<br /> 8.4.3.1. Key country dynamics<br /> 8.4.3.2. Regulatory framework/ reimbursement structure<br /> 8.4.3.3. Competitive scenario<br /> 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.4. Italy<br /> 8.4.4.1. Key country dynamics<br /> 8.4.4.2. Regulatory framework/ reimbursement structure<br /> 8.4.4.3. Competitive scenario<br /> 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.5. Spain<br /> 8.4.5.1. Key country dynamics<br /> 8.4.5.2. Regulatory framework/ reimbursement structure<br /> 8.4.5.3. Competitive scenario<br /> 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.6. Norway<br /> 8.4.6.1. Key country dynamics<br /> 8.4.6.2. Regulatory framework/ reimbursement structure<br /> 8.4.6.3. Competitive scenario<br /> 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.7. Sweden<br /> 8.4.7.1. Key country dynamics<br /> 8.4.7.2. Regulatory framework/ reimbursement structure<br /> 8.4.7.3. Competitive scenario<br /> 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.8. Denmark<br /> 8.4.8.1. Key country dynamics<br /> 8.4.8.2. Regulatory framework/ reimbursement structure<br /> 8.4.8.3. Competitive scenario<br /> 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5. Asia Pacific<br /> 8.5.1. Japan<br /> 8.5.1.1. Key country dynamics<br /> 8.5.1.2. Regulatory framework/ reimbursement structure<br /> 8.5.1.3. Competitive scenario<br /> 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.2. China<br /> 8.5.2.1. Key country dynamics<br /> 8.5.2.2. Regulatory framework/ reimbursement structure<br /> 8.5.2.3. Competitive scenario<br /> 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.3. India<br /> 8.5.3.1. Key country dynamics<br /> 8.5.3.2. Regulatory framework/ reimbursement structure<br /> 8.5.3.3. Competitive scenario<br /> 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.4. Australia<br /> 8.5.4.1. Key country dynamics<br /> 8.5.4.2. Regulatory framework/ reimbursement structure<br /> 8.5.4.3. Competitive scenario<br /> 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.5. South Korea<br /> 8.5.5.1. Key country dynamics<br /> 8.5.5.2. Regulatory framework/ reimbursement structure<br /> 8.5.5.3. Competitive scenario<br /> 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.6. Thailand<br /> 8.5.6.1. Key country dynamics<br /> 8.5.6.2. Regulatory framework/ reimbursement structure<br /> 8.5.6.3. Competitive scenario<br /> 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6. Latin America<br /> 8.6.1. Brazil<br /> 8.6.1.1. Key country dynamics<br /> 8.6.1.2. Regulatory framework/ reimbursement structure<br /> 8.6.1.3. Competitive scenario<br /> 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6.2. Argentina<br /> 8.6.2.1. Key country dynamics<br /> 8.6.2.2. Regulatory framework/ reimbursement structure<br /> 8.6.2.3. Competitive scenario<br /> 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7. MEA<br /> 8.7.1. South Africa<br /> 8.7.1.1. Key country dynamics<br /> 8.7.1.2. Regulatory framework/ reimbursement structure<br /> 8.7.1.3. Competitive scenario<br /> 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.2. Saudi Arabia<br /> 8.7.2.1. Key country dynamics<br /> 8.7.2.2. Regulatory framework/ reimbursement structure<br /> 8.7.2.3. Competitive scenario<br /> 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.3. UAE<br /> 8.7.3.1. Key country dynamics<br /> 8.7.3.2. Regulatory framework/ reimbursement structure<br /> 8.7.3.3. Competitive scenario<br /> 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.4. Kuwait<br /> 8.7.4.1. Key country dynamics<br /> 8.7.4.2. Regulatory framework/ reimbursement structure<br /> 8.7.4.3. Competitive scenario<br /> 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 9. Competitive Landscape</span> <br /> 9.1. Company/Competition Categorization<br /> 9.2. Vendor Landscape<br /> 9.2.1. List of key distributors and channel partners<br /> 9.2.2. Key customers<br /> 9.2.3. Key company market share analysis, 2023<br /> 9.2.4. Astellas Pharma Inc.<br /> 9.2.4.1. Company overview<br /> 9.2.4.2. Financial performance<br /> 9.2.4.3. Product benchmarking<br /> 9.2.4.4. Strategic initiatives<br /> 9.2.5. Bristol Myers Squibb Company<br /> 9.2.5.1. Company overview<br /> 9.2.5.2. Financial performance<br /> 9.2.5.3. Product benchmarking<br /> 9.2.5.4. Strategic initiatives<br /> 9.2.6. Celgene Corporation<br /> 9.2.6.1. Company overview<br /> 9.2.6.2. Financial performance<br /> 9.2.6.3. Product benchmarking<br /> 9.2.6.4. Strategic initiatives<br /> 9.2.7. Daiichi Sankyo Company, Limited<br /> 9.2.7.1. Company overview<br /> 9.2.7.2. Financial performance<br /> 9.2.7.3. Product benchmarking<br /> 9.2.7.4. Strategic initiatives<br /> 9.2.8. Jazz Pharmaceuticals, plc<br /> 9.2.8.1. Company overview<br /> 9.2.8.2. Financial performance<br /> 9.2.8.3. Product benchmarking<br /> 9.2.8.4. Strategic initiatives<br /> 9.2.9. Novartis AG<br /> 9.2.9.1. Company overview<br /> 9.2.9.2. Financial performance<br /> 9.2.9.3. Product benchmarking<br /> 9.2.9.4. Strategic initiatives<br /> 9.2.10. Otsuka Pharmaceuticals Co., Ltd.<br /> 9.2.10.1. Company overview<br /> 9.2.10.2. Financial performance<br /> 9.2.10.3. Product benchmarking<br /> 9.2.10.4. Strategic initiatives<br /> 9.2.11. Pfizer, Inc.<br /> 9.2.11.1. Company overview<br /> 9.2.11.2. Financial performance<br /> 9.2.11.3. Product benchmarking<br /> 9.2.11.4. Strategic initiatives<br /> 9.2.12. Rigel Pharmaceuticals, Inc.<br /> 9.2.12.1. Company overview<br /> 9.2.12.2. Financial performance<br /> 9.2.12.3. Product benchmarking<br /> 9.2.12.4. Strategic initiatives<br /> 9.2.13. Merck & Co., Inc.<br /> 9.2.13.1. Company overview<br /> 9.2.13.2. Financial performance<br /> 9.2.13.3. Product benchmarking<br /> 9.2.13.4. Strategic initiatives<br /> 9.2.14. Sanofi<br /> 9.2.14.1. Company overview<br /> 9.2.14.2. Financial performance<br /> 9.2.14.3. Product<br /> 9.2.14.4. Benchmarking<br /> 9.2.14.5. Strategic initiatives </p> <p> <span style="font-weight:bold;">List of Tables</span> <br /> Table 1 List of abbreviation<br /> Table 2 North America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 3 North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 4 North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 5 North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 6 North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 7 U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 8 U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 9 U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 10 U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 11 Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 12 Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 13 Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 14 Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 15 Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 16 Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 17 Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 18 Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 19 Europe acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 20 Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 21 Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 22 Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 23 Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 24 Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 25 Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 26 Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 27 Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 28 UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 29 UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 30 UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 31 UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 32 France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 33 France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 34 France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 35 France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 36 Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 37 Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 38 Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 39 Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 40 Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 41 Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 42 Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 43 Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 44 Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 45 Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 46 Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 47 Denmark Acute Myeloid Leukemia Treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 48 Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 49 Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 50 Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 51 Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 52 Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 53 Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 54 Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 55 Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 56 Asia Pacific acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 57 Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 58 Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 59 Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 60 Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 61 China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 62 China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 63 China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 64 China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 65 Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 66 Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 67 Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 68 Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 69 India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 70 India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 71 India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 72 India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 73 South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 74 South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 75 South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 76 South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 77 Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 78 Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 79 Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 80 Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 81 Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 82 Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 83 Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 84 Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 85 Latin America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 86 Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 87 Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 88 Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 89 Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 90 Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 91 Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 92 Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 93 Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 94 Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 95 Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 96 Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 97 Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 98 MEA acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 99 MEA acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 100 MEA acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 101 MEA acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 102 MEA acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 103 South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 104 South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 105 South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 106 South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 107 Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 108 Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 109 Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 110 Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 111 UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 112 UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 113 UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 114 UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 115 Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 116 Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 117 Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 118 Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million) </p> <p> <span style="font-weight:bold;">List of Figures</span> <br /> Fig. 1 Market research process<br /> Fig. 2 Data triangulation techniques<br /> Fig. 3 Primary research pattern<br /> Fig. 4 Primary interviews in North America<br /> Fig. 5 Primary interviews in Europe<br /> Fig. 6 Primary interviews in APAC<br /> Fig. 7 Primary interviews in Latin America<br /> Fig. 8 Primary interviews in MEA<br /> Fig. 9 Market research approaches<br /> Fig. 10 Value-chain-based sizing & forecasting<br /> Fig. 11 QFD modeling for market share assessment<br /> Fig. 12 Market formulation & validation<br /> Fig. 13 Acute myeloid leukemia treatment market: market outlook<br /> Fig. 14 Acute myeloid leukemia treatment competitive insights<br /> Fig. 15 Parent market outlook<br /> Fig. 16 Related/ancillary market outlook<br /> Fig. 17 Acute myeloid leukemia treatment market driver impact<br /> Fig. 18 Acute myeloid leukemia treatment market restraint impact<br /> Fig. 19 Acute myeloid leukemia treatment market: disease movement analysis<br /> Fig. 20 Acute myeloid leukemia treatment market: disease outlook and key takeaways<br /> Fig. 21 Myeloblastic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 22 Myelomonocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 23 Promyelocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 25 Monocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 26 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 27 Acute myeloid leukemia treatment market: Treatment movement analysis<br /> Fig. 28 Acute myeloid leukemia treatment market: Treatment outlook and key takeaways<br /> Fig. 29 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 30 Anti-metabolites market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 31 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 32 Anthracycline drugs market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 34 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 35 FLT3 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 36 Rydapt market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 37 Vanflyta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 38 Xospata market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 39 IDH inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 40 Tibsovo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 41 Rezlidhia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 42 Idhifa market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 43 Mylotarg market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 44 BCL-2 inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 45 Venclexta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 46 Hedgehog pathway inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 47 Daurismo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 48 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 49 Bispecific antibodies market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 50 Antibody-drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 51 Immune checkpoint inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 52 Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 53 Other treatments market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 54 Acute myeloid leukemia treatment market: Route of administration movement analysis<br /> Fig. 55 Acute myeloid leukemia treatment market: Route of administration outlook and key takeaways<br /> Fig. 56 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 57 Oral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 58 Acute myeloid leukemia treatment market: End Use movement analysis<br /> Fig. 59 Acute myeloid leukemia treatment market: End Use outlook and key takeaways<br /> Fig. 60 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 61 Specialty centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 62 Homecare setting market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 63 Ambulatory care centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 64 Global acute myeloid leukemia treatment market: Regional movement analysis<br /> Fig. 65 Global acute myeloid leukemia treatment market: Regional outlook and key takeaways<br /> Fig. 66 Global acute myeloid leukemia treatment market share and leading players<br /> Fig. 67 North America, by country<br /> Fig. 68 North America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 69 U.S. key country dynamics<br /> Fig. 70 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 71 Canada key country dynamics<br /> Fig. 72 Canada market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 73 Mexico key country dynamics<br /> Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 75 Europe market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 76 UK key country dynamics<br /> Fig. 77 UK market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 78 Germany key country dynamics<br /> Fig. 79 Germany market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 80 France key country dynamics<br /> Fig. 81 France market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 82 Italy key country dynamics<br /> Fig. 83 Italy market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 84 Spain key country dynamics<br /> Fig. 85 Spain market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 86 Denmark key country dynamics<br /> Fig. 87 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 88 Sweden key country dynamics<br /> Fig. 89 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 90 Norway key country dynamics<br /> Fig. 91 Norway market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 93 China key country dynamics<br /> Fig. 94 China market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 95 Japan key country dynamics<br /> Fig. 96 Japan market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 97 India key country dynamics<br /> Fig. 98 India market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 99 Thailand key country dynamics<br /> Fig. 100 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 101 South Korea key country dynamics<br /> Fig. 102 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 103 Australia key country dynamics<br /> Fig. 104 Australia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 105 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 106 Brazil key country dynamics<br /> Fig. 107 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 108 Argentina key country dynamics<br /> Fig. 109 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 110 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 111 South Africa key country dynamics<br /> Fig. 112 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 113 Saudi Arabia key country dynamics<br /> Fig. 114 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 115 UAE key country dynamics<br /> Fig. 116 UAE market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 117 Kuwait key country dynamics<br /> Fig. 118 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 119 Market share of key market players- acute myeloid leukemia treatment market </p> </div> </div><!--/report_discription--> <div class="btn_report_set"> <div class="btn01"> <a href="/guides">ãŠè²·ã„物ガイド</a> </div><!--/btn01--> <div class="btn01"> <a href="/questions">よãã‚る質å•</a> </div><!--/btn01--> </div><!--/btn_report_set--> <div class="tel_guide clearfix"> <a href="tel:0358125270"><img src="/img/./category/suport_tel_03.jpg" alt=""/></a> <div class="report_no"> <p>ã“ã®å•†å“ã®ãƒ¬ãƒãƒ¼ãƒˆãƒŠãƒ³ãƒãƒ¼</p> <p class="report_no_box">0000039052</p> </div> </div><!--/tel_guide--> </div> </form> </div> <script type="text/javascript"> $('#carts_add').css("cursor","pointer"); $('#carts_now').css("cursor","pointer"); $('#heart_off').css("cursor","pointer"); $('.heart_off').css("cursor","pointer"); $(function(){ if($('#stlist').length){ $('.btn_cart').fadeOut(); } }); $(function () { $('.tooltip_favorite').hide(); $('div').hover( function () { $(this).children('.tooltip_favorite').fadeIn('fast'); }, function () { $(this).children('.tooltip_favorite').fadeOut('fast'); }); }); </script> ', 'scripts_for_layout' => '', 'title_for_layout' => 'Categories' ) $favorite_data = array() $keywords = array( (int) 0 => '急性骨髄性白血病治療薬', (int) 1 => '予測' ) $summary = array() $rrc = array( (int) 0 => array( 'ReportRelationCategory' => array( 'id' => '66829', 'report_id' => '39052', 'category_id' => '2', 'subcategory_id' => '1', 'old_category_id' => null, 'old_subcategory_id' => null, 'update_date' => '2024-08-19 14:21:48' ) ), (int) 1 => array( 'ReportRelationCategory' => array( 'id' => '66830', 'report_id' => '39052', 'category_id' => '2', 'subcategory_id' => '3', 'old_category_id' => null, 'old_subcategory_id' => null, 'update_date' => '2024-08-19 14:21:48' ) ) ) $rrr_report_base_res = array() $report_detail = array( (int) 0 => array( 'id' => '46865', 'order_num' => '1', 'report_id' => '39052', 'title' => '目次', 'body' => '<p> <span style="font-weight:bold;">Table of Contents</span> </p> <p> <span style="font-weight:bold;">Chapter 1. Methodology and Scope</span> <br /> 1.1. Market Segmentation & Scope<br /> 1.2. Segment Definitions<br /> 1.2.1. Disease<br /> 1.2.2. Treatment<br /> 1.2.3. Route of Administration<br /> 1.2.4. End Use<br /> 1.2.5. Regional scope<br /> 1.2.6. Estimates and forecasts timeline<br /> 1.3. Research Methodology<br /> 1.4. Information Procurement<br /> 1.4.1. Purchased database<br /> 1.4.2. GVR’s internal database<br /> 1.4.3. Secondary sources<br /> 1.4.4. Primary research<br /> 1.4.5. Details of primary research<br /> 1.4.5.1. Data for primary interviews in North America<br /> 1.4.5.2. Data for primary interviews in Europe<br /> 1.4.5.3. Data for primary interviews in Asia Pacific<br /> 1.4.5.4. Data for primary interviews in Latin America<br /> 1.4.5.5. Data for Primary interviews in MEA<br /> 1.5. Information or Data Analysis<br /> 1.5.1. Data analysis models<br /> 1.6. Market Formulation & Validation<br /> 1.7. Model Details<br /> 1.7.1. Commodity flow analysis (Model 1)<br /> 1.7.2. Approach 1: Commodity flow approach<br /> 1.7.3. Volume price analysis (Model 2)<br /> 1.7.4. Approach 2: Volume price analysis<br /> 1.8. List of Secondary Sources<br /> 1.9. List of Primary Sources<br /> 1.10. Objectives </p> <p> <span style="font-weight:bold;">Chapter 2. Executive Summary</span> <br /> 2.1. Market Outlook<br /> 2.2. Segment Outlook<br /> 2.2.1. Disease outlook<br /> 2.2.2. Treatment outlook<br /> 2.2.3. Route of Administration outlook<br /> 2.2.4. End Use outlook<br /> 2.2.5. Regional outlook<br /> 2.3. Competitive Insights </p> <p> <span style="font-weight:bold;">Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope</span> <br /> 3.1. Market Lineage Outlook<br /> 3.1.1. Parent market outlook<br /> 3.1.2. Related/ancillary market outlook<br /> 3.2. Market Dynamics<br /> 3.2.1. Market driver analysis<br /> 3.2.1.1. Increasing prevalence of acute myeloid leukemia<br /> 3.2.1.2. Advancements in diagnostic techniques<br /> 3.2.1.3. Growing investments in R&D techniques<br /> 3.2.2. Market restraint analysis<br /> 3.2.2.1. High cost of treatment<br /> 3.2.2.2. Limited treatment options<br /> 3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools<br /> 3.3.1. Industry Analysis - Porter’s Five Forces<br /> 3.3.1.1. Supplier power<br /> 3.3.1.2. Buyer power<br /> 3.3.1.3. Substitution threat<br /> 3.3.1.4. Threat of new entrant<br /> 3.3.1.5. Competitive rivalry<br /> 3.3.2. PESTEL Analysis<br /> 3.3.2.1. Political landscape<br /> 3.3.2.2. Technological landscape<br /> 3.3.2.3. Economic landscape<br /> 3.3.3. Pipeline Analysis </p> <p> <span style="font-weight:bold;">Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis</span> <br /> 4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard<br /> 4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis<br /> 4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue<br /> 4.4. Myeloblastic Leukemia<br /> 4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.5. Myelomonocytic Leukemia<br /> 4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.6. Promyelocytic Leukemia<br /> 4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.7. Monocytic Leukemia<br /> 4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.8. Other Diseases<br /> 4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis</span> <br /> 5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard<br /> 5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis<br /> 5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)<br /> 5.4. Chemotherapy<br /> 5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.2. Anti-metabolites<br /> 5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.3. Alkylating agents<br /> 5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.4. Anthracycline drugs<br /> 5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.5. Others<br /> 5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5. Targeted Therapy<br /> 5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2. FLT3 inhibitors<br /> 5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.1. Rydapt<br /> 5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.2. Vanflyta<br /> 5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.3. Xospata<br /> 5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3. IDH inhibitors<br /> 5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.1. Tibsovo<br /> 5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.2. Rezlidhia<br /> 5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.3. Idhifa<br /> 5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.4. Mylotarg<br /> 5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5. BCL-2 inhibitor<br /> 5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5.1.1. Venclexta<br /> 5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6. Hedgehog pathway inhibitor<br /> 5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6.1.1. Daurismo<br /> 5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6. Immunotherapy<br /> 5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.1. Bispecific antibodies<br /> 5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.2. Antibody-drug conjugates<br /> 5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.4. Immune checkpoint inhibitors<br /> 5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy<br /> 5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.7. Other Treatments<br /> 5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis</span> <br /> 6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard<br /> 6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis<br /> 6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)<br /> 6.4. Parenteral<br /> 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)<br /> 6.5. Oral<br /> 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis</span> <br /> 7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard<br /> 7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis<br /> 7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)<br /> 7.4. Hospital and Clinics<br /> 7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.5. Specialty Centers<br /> 7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.6. Homecare Setting<br /> 7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration</span> <br /> 8.1. Regional Dashboard<br /> 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:<br /> 8.3. North America<br /> 8.3.1. U.S.<br /> 8.3.1.1. Key country dynamics<br /> 8.3.1.2. Regulatory framework/ reimbursement structure<br /> 8.3.1.3. Competitive scenario<br /> 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.2. Canada<br /> 8.3.2.1. Key country dynamics<br /> 8.3.2.2. Regulatory framework/ reimbursement structure<br /> 8.3.2.3. Competitive scenario<br /> 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.3. Mexico<br /> 8.3.3.1. Key country dynamics<br /> 8.3.3.2. Regulatory framework/ reimbursement structure<br /> 8.3.3.3. Competitive scenario<br /> 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4. Europe<br /> 8.4.1. UK<br /> 8.4.1.1. Key country dynamics<br /> 8.4.1.2. Regulatory framework/ reimbursement structure<br /> 8.4.1.3. Competitive scenario<br /> 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.2. Germany<br /> 8.4.2.1. Key country dynamics<br /> 8.4.2.2. Regulatory framework/ reimbursement structure<br /> 8.4.2.3. Competitive scenario<br /> 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.3. France<br /> 8.4.3.1. Key country dynamics<br /> 8.4.3.2. Regulatory framework/ reimbursement structure<br /> 8.4.3.3. Competitive scenario<br /> 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.4. Italy<br /> 8.4.4.1. Key country dynamics<br /> 8.4.4.2. Regulatory framework/ reimbursement structure<br /> 8.4.4.3. Competitive scenario<br /> 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.5. Spain<br /> 8.4.5.1. Key country dynamics<br /> 8.4.5.2. Regulatory framework/ reimbursement structure<br /> 8.4.5.3. Competitive scenario<br /> 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.6. Norway<br /> 8.4.6.1. Key country dynamics<br /> 8.4.6.2. Regulatory framework/ reimbursement structure<br /> 8.4.6.3. Competitive scenario<br /> 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.7. Sweden<br /> 8.4.7.1. Key country dynamics<br /> 8.4.7.2. Regulatory framework/ reimbursement structure<br /> 8.4.7.3. Competitive scenario<br /> 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.8. Denmark<br /> 8.4.8.1. Key country dynamics<br /> 8.4.8.2. Regulatory framework/ reimbursement structure<br /> 8.4.8.3. Competitive scenario<br /> 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5. Asia Pacific<br /> 8.5.1. Japan<br /> 8.5.1.1. Key country dynamics<br /> 8.5.1.2. Regulatory framework/ reimbursement structure<br /> 8.5.1.3. Competitive scenario<br /> 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.2. China<br /> 8.5.2.1. Key country dynamics<br /> 8.5.2.2. Regulatory framework/ reimbursement structure<br /> 8.5.2.3. Competitive scenario<br /> 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.3. India<br /> 8.5.3.1. Key country dynamics<br /> 8.5.3.2. Regulatory framework/ reimbursement structure<br /> 8.5.3.3. Competitive scenario<br /> 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.4. Australia<br /> 8.5.4.1. Key country dynamics<br /> 8.5.4.2. Regulatory framework/ reimbursement structure<br /> 8.5.4.3. Competitive scenario<br /> 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.5. South Korea<br /> 8.5.5.1. Key country dynamics<br /> 8.5.5.2. Regulatory framework/ reimbursement structure<br /> 8.5.5.3. Competitive scenario<br /> 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.6. Thailand<br /> 8.5.6.1. Key country dynamics<br /> 8.5.6.2. Regulatory framework/ reimbursement structure<br /> 8.5.6.3. Competitive scenario<br /> 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6. Latin America<br /> 8.6.1. Brazil<br /> 8.6.1.1. Key country dynamics<br /> 8.6.1.2. Regulatory framework/ reimbursement structure<br /> 8.6.1.3. Competitive scenario<br /> 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6.2. Argentina<br /> 8.6.2.1. Key country dynamics<br /> 8.6.2.2. Regulatory framework/ reimbursement structure<br /> 8.6.2.3. Competitive scenario<br /> 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7. MEA<br /> 8.7.1. South Africa<br /> 8.7.1.1. Key country dynamics<br /> 8.7.1.2. Regulatory framework/ reimbursement structure<br /> 8.7.1.3. Competitive scenario<br /> 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.2. Saudi Arabia<br /> 8.7.2.1. Key country dynamics<br /> 8.7.2.2. Regulatory framework/ reimbursement structure<br /> 8.7.2.3. Competitive scenario<br /> 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.3. UAE<br /> 8.7.3.1. Key country dynamics<br /> 8.7.3.2. Regulatory framework/ reimbursement structure<br /> 8.7.3.3. Competitive scenario<br /> 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.4. Kuwait<br /> 8.7.4.1. Key country dynamics<br /> 8.7.4.2. Regulatory framework/ reimbursement structure<br /> 8.7.4.3. Competitive scenario<br /> 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 9. Competitive Landscape</span> <br /> 9.1. Company/Competition Categorization<br /> 9.2. Vendor Landscape<br /> 9.2.1. List of key distributors and channel partners<br /> 9.2.2. Key customers<br /> 9.2.3. Key company market share analysis, 2023<br /> 9.2.4. Astellas Pharma Inc.<br /> 9.2.4.1. Company overview<br /> 9.2.4.2. Financial performance<br /> 9.2.4.3. Product benchmarking<br /> 9.2.4.4. Strategic initiatives<br /> 9.2.5. Bristol Myers Squibb Company<br /> 9.2.5.1. Company overview<br /> 9.2.5.2. Financial performance<br /> 9.2.5.3. Product benchmarking<br /> 9.2.5.4. Strategic initiatives<br /> 9.2.6. Celgene Corporation<br /> 9.2.6.1. Company overview<br /> 9.2.6.2. Financial performance<br /> 9.2.6.3. Product benchmarking<br /> 9.2.6.4. Strategic initiatives<br /> 9.2.7. Daiichi Sankyo Company, Limited<br /> 9.2.7.1. Company overview<br /> 9.2.7.2. Financial performance<br /> 9.2.7.3. Product benchmarking<br /> 9.2.7.4. Strategic initiatives<br /> 9.2.8. Jazz Pharmaceuticals, plc<br /> 9.2.8.1. Company overview<br /> 9.2.8.2. Financial performance<br /> 9.2.8.3. Product benchmarking<br /> 9.2.8.4. Strategic initiatives<br /> 9.2.9. Novartis AG<br /> 9.2.9.1. Company overview<br /> 9.2.9.2. Financial performance<br /> 9.2.9.3. Product benchmarking<br /> 9.2.9.4. Strategic initiatives<br /> 9.2.10. Otsuka Pharmaceuticals Co., Ltd.<br /> 9.2.10.1. Company overview<br /> 9.2.10.2. Financial performance<br /> 9.2.10.3. Product benchmarking<br /> 9.2.10.4. Strategic initiatives<br /> 9.2.11. Pfizer, Inc.<br /> 9.2.11.1. Company overview<br /> 9.2.11.2. Financial performance<br /> 9.2.11.3. Product benchmarking<br /> 9.2.11.4. Strategic initiatives<br /> 9.2.12. Rigel Pharmaceuticals, Inc.<br /> 9.2.12.1. Company overview<br /> 9.2.12.2. Financial performance<br /> 9.2.12.3. Product benchmarking<br /> 9.2.12.4. Strategic initiatives<br /> 9.2.13. Merck & Co., Inc.<br /> 9.2.13.1. Company overview<br /> 9.2.13.2. Financial performance<br /> 9.2.13.3. Product benchmarking<br /> 9.2.13.4. Strategic initiatives<br /> 9.2.14. Sanofi<br /> 9.2.14.1. Company overview<br /> 9.2.14.2. Financial performance<br /> 9.2.14.3. Product<br /> 9.2.14.4. Benchmarking<br /> 9.2.14.5. Strategic initiatives </p> <p> <span style="font-weight:bold;">List of Tables</span> <br /> Table 1 List of abbreviation<br /> Table 2 North America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 3 North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 4 North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 5 North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 6 North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 7 U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 8 U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 9 U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 10 U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 11 Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 12 Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 13 Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 14 Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 15 Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 16 Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 17 Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 18 Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 19 Europe acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 20 Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 21 Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 22 Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 23 Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 24 Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 25 Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 26 Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 27 Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 28 UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 29 UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 30 UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 31 UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 32 France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 33 France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 34 France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 35 France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 36 Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 37 Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 38 Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 39 Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 40 Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 41 Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 42 Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 43 Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 44 Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 45 Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 46 Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 47 Denmark Acute Myeloid Leukemia Treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 48 Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 49 Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 50 Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 51 Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 52 Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 53 Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 54 Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 55 Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 56 Asia Pacific acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 57 Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 58 Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 59 Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 60 Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 61 China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 62 China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 63 China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 64 China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 65 Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 66 Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 67 Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 68 Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 69 India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 70 India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 71 India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 72 India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 73 South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 74 South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 75 South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 76 South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 77 Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 78 Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 79 Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 80 Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 81 Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 82 Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 83 Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 84 Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 85 Latin America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 86 Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 87 Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 88 Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 89 Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 90 Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 91 Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 92 Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 93 Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 94 Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 95 Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 96 Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 97 Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 98 MEA acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 99 MEA acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 100 MEA acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 101 MEA acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 102 MEA acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 103 South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 104 South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 105 South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 106 South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 107 Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 108 Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 109 Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 110 Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 111 UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 112 UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 113 UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 114 UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 115 Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 116 Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 117 Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 118 Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million) </p> <p> <span style="font-weight:bold;">List of Figures</span> <br /> Fig. 1 Market research process<br /> Fig. 2 Data triangulation techniques<br /> Fig. 3 Primary research pattern<br /> Fig. 4 Primary interviews in North America<br /> Fig. 5 Primary interviews in Europe<br /> Fig. 6 Primary interviews in APAC<br /> Fig. 7 Primary interviews in Latin America<br /> Fig. 8 Primary interviews in MEA<br /> Fig. 9 Market research approaches<br /> Fig. 10 Value-chain-based sizing & forecasting<br /> Fig. 11 QFD modeling for market share assessment<br /> Fig. 12 Market formulation & validation<br /> Fig. 13 Acute myeloid leukemia treatment market: market outlook<br /> Fig. 14 Acute myeloid leukemia treatment competitive insights<br /> Fig. 15 Parent market outlook<br /> Fig. 16 Related/ancillary market outlook<br /> Fig. 17 Acute myeloid leukemia treatment market driver impact<br /> Fig. 18 Acute myeloid leukemia treatment market restraint impact<br /> Fig. 19 Acute myeloid leukemia treatment market: disease movement analysis<br /> Fig. 20 Acute myeloid leukemia treatment market: disease outlook and key takeaways<br /> Fig. 21 Myeloblastic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 22 Myelomonocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 23 Promyelocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 25 Monocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 26 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 27 Acute myeloid leukemia treatment market: Treatment movement analysis<br /> Fig. 28 Acute myeloid leukemia treatment market: Treatment outlook and key takeaways<br /> Fig. 29 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 30 Anti-metabolites market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 31 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 32 Anthracycline drugs market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 34 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 35 FLT3 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 36 Rydapt market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 37 Vanflyta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 38 Xospata market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 39 IDH inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 40 Tibsovo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 41 Rezlidhia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 42 Idhifa market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 43 Mylotarg market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 44 BCL-2 inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 45 Venclexta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 46 Hedgehog pathway inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 47 Daurismo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 48 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 49 Bispecific antibodies market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 50 Antibody-drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 51 Immune checkpoint inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 52 Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 53 Other treatments market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 54 Acute myeloid leukemia treatment market: Route of administration movement analysis<br /> Fig. 55 Acute myeloid leukemia treatment market: Route of administration outlook and key takeaways<br /> Fig. 56 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 57 Oral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 58 Acute myeloid leukemia treatment market: End Use movement analysis<br /> Fig. 59 Acute myeloid leukemia treatment market: End Use outlook and key takeaways<br /> Fig. 60 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 61 Specialty centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 62 Homecare setting market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 63 Ambulatory care centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 64 Global acute myeloid leukemia treatment market: Regional movement analysis<br /> Fig. 65 Global acute myeloid leukemia treatment market: Regional outlook and key takeaways<br /> Fig. 66 Global acute myeloid leukemia treatment market share and leading players<br /> Fig. 67 North America, by country<br /> Fig. 68 North America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 69 U.S. key country dynamics<br /> Fig. 70 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 71 Canada key country dynamics<br /> Fig. 72 Canada market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 73 Mexico key country dynamics<br /> Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 75 Europe market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 76 UK key country dynamics<br /> Fig. 77 UK market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 78 Germany key country dynamics<br /> Fig. 79 Germany market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 80 France key country dynamics<br /> Fig. 81 France market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 82 Italy key country dynamics<br /> Fig. 83 Italy market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 84 Spain key country dynamics<br /> Fig. 85 Spain market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 86 Denmark key country dynamics<br /> Fig. 87 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 88 Sweden key country dynamics<br /> Fig. 89 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 90 Norway key country dynamics<br /> Fig. 91 Norway market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 93 China key country dynamics<br /> Fig. 94 China market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 95 Japan key country dynamics<br /> Fig. 96 Japan market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 97 India key country dynamics<br /> Fig. 98 India market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 99 Thailand key country dynamics<br /> Fig. 100 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 101 South Korea key country dynamics<br /> Fig. 102 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 103 Australia key country dynamics<br /> Fig. 104 Australia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 105 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 106 Brazil key country dynamics<br /> Fig. 107 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 108 Argentina key country dynamics<br /> Fig. 109 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 110 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 111 South Africa key country dynamics<br /> Fig. 112 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 113 Saudi Arabia key country dynamics<br /> Fig. 114 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 115 UAE key country dynamics<br /> Fig. 116 UAE market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 117 Kuwait key country dynamics<br /> Fig. 118 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 119 Market share of key market players- acute myeloid leukemia treatment market </p> ', 'update_date' => '2024-08-19 14:22:18' ) ) $report_pdf = array() $report_base = array( 'id' => '39052', 'pj_code' => '999999', 'title_main' => 'æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030', 'title_volume' => '', 'title_volumetitle' => '', 'charge_person' => '37', 'subtitle' => 'Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030', 'keyword1' => '急性骨髄性白血病治療薬', 'keyword2' => '予測', 'keyword3' => '', 'keyword4' => '', 'keyword5' => '', 'summary1' => '', 'summary2' => '', 'summary3' => '', 'language' => '2', 'disp_status' => '1', 'publish_status' => '1', 'publish_date' => '2024-07-01', 'publish_date_ymdsp' => true, 'publish_check' => null, 'price_reserve' => '0', 'price_reserve2' => '0', 'price_reserve3' => '0', 'price_reserve4' => '0', 'price_reserve5' => '0', 'license_reserve' => '', 'license_reserve2' => '', 'license_reserve3' => '', 'license_reserve4' => '', 'license_reserve5' => '', 'price' => '5950', 'price2' => '6950', 'price3' => '8950', 'price4' => '0', 'price5' => '0', 'price6' => '0', 'price7' => '0', 'price8' => '0', 'license' => 'Individual', 'license2' => 'Team', 'license3' => 'Enterprise', 'license4' => '', 'license5' => '', 'license6' => '', 'license7' => '', 'license8' => '', 'unit_e' => null, 'unit' => 'USD', 'style_format' => 'PDF', 'about_flag' => '0', 'style_page' => '175', 'publishing_office' => 'Grand View Research Inc.', 'note' => '※ã”請求ã¯ã€ãŠç”³è¾¼æ—¥ã®TTSレートã§å††æ›ç®—ã—ã€æ¶ˆè²»ç¨Žã‚’åŠ ãˆãŸé‡‘é¡ã«ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯ã€è‹±æ–‡ã§ã™ã€‚PDF(é›»å媒体)ã§ã®ç´å“ã¨ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯å–り寄ã›ã¨ãªã‚Šã¾ã™ã®ã§ã€ç”³ã—è¾¼ã¿ã‹ã‚‰ãŠå±Šã‘ã¾ã§ã€å¤šå°‘時間ãŒæŽ›ã‹ã‚‹å ´åˆãŒã”ã–ã„ã¾ã™ã€‚', 'color' => '2', 'scolor' => null, 'outline' => '<p> <span style="font-weight:bold;">急性骨髄性白血病治療ã®å¸‚å ´è¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆï¼šç–¾æ‚£åˆ¥ (骨髄芽çƒæ€§ç™½è¡€ç—…ã€éª¨é«„å˜çƒæ€§ç™½è¡€ç—…)ã€æ²»ç™‚別 (化å¦ç™‚法)ã€æŠ•ä¸ŽçµŒè·¯åˆ¥ã€æœ€çµ‚用途別ã€åœ°åŸŸåˆ¥ã€ã‚»ã‚°ãƒ¡ãƒ³ãƒˆåˆ¥äºˆæ¸¬ã€2024-2030 </span> </p> <p> <span style="font-weight:bold;">å¸‚å ´è¦æ¨¡ã¨å‹•å‘</span> </p> <p> 世界ã®æ€¥æ€§éª¨é«„性白血病治療薬ã®å¸‚å ´è¦æ¨¡ã¯ã€2023å¹´ã«31å„„8000万ドルã¨æŽ¨å®šã•ã‚Œã€2024å¹´ã‹ã‚‰2030å¹´ã«ã‹ã‘ã¦10.44%ã®CAGRã§æˆé•·ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚高度ãªæ²»ç™‚è–¬ã«å¯¾ã™ã‚‹ãƒ‹ãƒ¼ã‚ºã®é«˜ã¾ã‚Šã‚‚ã€ã“ã®å¸‚å ´ã«å¤§ããªå½±éŸ¿åŠ›ã‚’æŒã¤æŽ¨é€²è¦å› ã§ã™ã€‚急性骨髄性白血病治療薬ã®ç™ºç”ŸçŽ‡ã®ä¸Šæ˜‡ã¯ã€éºä¼å変異ã€ä¸å¥åº·ãªç”Ÿæ´»ç¿’æ…£ã€ãƒ™ãƒ³ã‚¼ãƒ³ãªã©ã®æœ‰å®³åŒ–å¦ç‰©è³ªã¸ã®ç¶™ç¶šçš„ãªæ›éœ²ã€æ”¾å°„線被ã°ããªã©ã®è¦å› ã«èµ·å› ã—ã¦ã„ã¾ã™ã€‚ã•ã‚‰ã«ã€é«˜é½¢è€…人å£ã®å¢—åŠ ã¨æº€ãŸã•ã‚Œã¦ã„ãªã„医療ニーズã®é«˜ã¾ã‚ŠãŒã€å¸‚å ´ã®æˆé•·ã‚’ã•ã‚‰ã«å¾ŒæŠ¼ã—ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚2024å¹´ã«ç±³å›½ãŒã‚“å”会ãŒç™ºè¡¨ã—ãŸæŽ¨å®šã«ã‚ˆã‚‹ã¨ã€ç´„20,800人ãŒæ€¥æ€§éª¨é«„性白血病ã¨è¨ºæ–ã•ã‚Œã¾ã—ãŸã€‚ </p> ', 'memo' => 'https://www.grandviewresearch.com/industry-analysis/acute-myeloid-leukemia-therapeutics-market', 'catalog_copy' => '', 'pamphlet_pdf' => '0', 's_upload' => null, 'i_upload' => '1', 'update_flag' => null, 'update_date' => '2024-08-19 14:21:48', 'regist_date' => '0000-00-00 00:00:00' ) $session_carts = array() $id = null $checked_reports = array() $category_list = array( (int) 1 => array( (int) 1 => array( 'subcategory_id' => '1', 'subcategory_name' => 'デジタル放é€ãƒ»CATV', 'category_id' => '1' ), (int) 2 => array( 'subcategory_id' => '2', 'subcategory_name' => 'インターãƒãƒƒãƒˆé€šä¿¡ã‚¤ãƒ³ãƒ•ãƒ©eビジãƒã‚¹', 'category_id' => '1' ), (int) 3 => array( 'subcategory_id' => '3', 'subcategory_name' => 'æºå¸¯é›»è©±ãƒ¢ãƒã‚¤ãƒ«', 'category_id' => '1' ), (int) 4 => array( 'subcategory_id' => '4', 'subcategory_name' => 'カーエレクトãƒãƒ‹ã‚¯ã‚¹ãƒ»ITS', 'category_id' => '1' ), (int) 5 => array( 'subcategory_id' => '5', 'subcategory_name' => 'ホームãƒãƒƒãƒˆãƒ¯ãƒ¼ã‚¯æƒ…å ±å®¶é›»AV', 'category_id' => '1' ), (int) 6 => array( 'subcategory_id' => '6', 'subcategory_name' => 'DVDHDDメモリーカードデータストレージ', 'category_id' => '1' ), (int) 7 => array( 'subcategory_id' => '7', 'subcategory_name' => 'å¤§åž‹æ˜ åƒãƒ»ãƒ‡ã‚£ã‚¹ãƒ—レイ', 'category_id' => '1' ), (int) 8 => array( 'subcategory_id' => '8', 'subcategory_name' => 'デジタルコンテンツ・エンターテインメント', 'category_id' => '1' ), (int) 9 => array( 'subcategory_id' => '9', 'subcategory_name' => 'エレクトãƒãƒ‹ã‚¯ã‚¹ãƒ»IT(ãã®ä»–)', 'category_id' => '1' ) ), (int) 2 => array( (int) 1 => array( 'subcategory_id' => '1', 'subcategory_name' => '医薬å“原料・製剤', 'category_id' => '2' ), (int) 2 => array( 'subcategory_id' => '2', 'subcategory_name' => '創薬一般', 'category_id' => '2' ), (int) 3 => array( 'subcategory_id' => '3', 'subcategory_name' => 'ç–¾ç—…åˆ¥æ²»ç™‚ãƒ»é ˜åŸŸåˆ¥æ²»ç™‚', 'category_id' => '2' ), (int) 4 => array( 'subcategory_id' => '4', 'subcategory_name' => 'ãƒã‚¤ã‚ªãƒ»ã‚²ãƒŽãƒ ・å†ç”ŸåŒ»ç™‚', 'category_id' => '2' ), (int) 5 => array( 'subcategory_id' => '5', 'subcategory_name' => '診æ–・検査薬', 'category_id' => '2' ), (int) 6 => array( 'subcategory_id' => '6', 'subcategory_name' => 'アウトソーシング', 'category_id' => '2' ), (int) 7 => array( 'subcategory_id' => '7', 'subcategory_name' => 'ä¼æ¥', 'category_id' => '2' ), (int) 8 => array( 'subcategory_id' => '8', 'subcategory_name' => '医薬å“産æ¥ï¼ˆåŒ»ç™‚制度ã€åŒ»ç™‚観光ãªã©ï¼‰', 'category_id' => '2' ), (int) 9 => array( 'subcategory_id' => '9', 'subcategory_name' => '医療器具・機器', 'category_id' => '2' ), (int) 10 => array( 'subcategory_id' => '10', 'subcategory_name' => 'メディカル・ãƒã‚¤ã‚ª(ãã®ä»–)', 'category_id' => '2' ) ), (int) 3 => array( (int) 1 => array( 'subcategory_id' => '1', 'subcategory_name' => '介è·ç¦ç¥‰', 'category_id' => '3' ), (int) 2 => array( 'subcategory_id' => '2', 'subcategory_name' => 'å¥åº·ãƒ»å¥åº·é£Ÿå“・特定ä¿å¥ç”¨é£Ÿå“', 'category_id' => '3' ), (int) 3 => array( 'subcategory_id' => '3', 'subcategory_name' => 'å¥åº·é£Ÿäº‹æŒ‡å°Ž', 'category_id' => '3' ), (int) 4 => array( 'subcategory_id' => '4', 'subcategory_name' => 'å¥åº·ä¿é™º', 'category_id' => '3' ), (int) 5 => array( 'subcategory_id' => '5', 'subcategory_name' => 'メンタルヘルス', 'category_id' => '3' ), (int) 6 => array( 'subcategory_id' => '6', 'subcategory_name' => 'ウエルãƒã‚¹(ãã®ä»–)', 'category_id' => '3' ) ), (int) 4 => array( (int) 1 => array( 'subcategory_id' => '1', 'subcategory_name' => '医療ＩＴ', 'category_id' => '4' ), (int) 2 => array( 'subcategory_id' => '2', 'subcategory_name' => '医療IT(ãã®ä»–)', 'category_id' => '4' ) ), (int) 5 => array( (int) 1 => array( 'subcategory_id' => '1', 'subcategory_name' => '石ç‚・石油・天然ガス', 'category_id' => '5' ), (int) 2 => array( 'subcategory_id' => '2', 'subcategory_name' => 'ãƒã‚¤ã‚ªç‡ƒæ–™(ãƒã‚¤ã‚ªãƒ‡ã‚£ãƒ¼ã‚¼ãƒ«ãƒ»ãƒã‚¤ã‚ªã‚¨ã‚¿ãƒŽãƒ¼ãƒ«)', 'category_id' => '5' ), (int) 3 => array( 'subcategory_id' => '3', 'subcategory_name' => 'スマートグリッド・スマートシティ', 'category_id' => '5' ), (int) 4 => array( 'subcategory_id' => '4', 'subcategory_name' => '太陽光', 'category_id' => '5' ), (int) 5 => array( 'subcategory_id' => '5', 'subcategory_name' => 'é›»æ± ãƒ»EV', 'category_id' => '5' ), (int) 6 => array( 'subcategory_id' => '6', 'subcategory_name' => '環境', 'category_id' => '5' ), (int) 7 => array( 'subcategory_id' => '7', 'subcategory_name' => 'エãƒãƒ«ã‚®ãƒ¼ãƒ»ç’°å¢ƒ(ãã®ä»–)', 'category_id' => '5' ) ), (int) 6 => array( (int) 1 => array( 'subcategory_id' => '1', 'subcategory_name' => 'å€‹äººæƒ…å ±ä¿è·', 'category_id' => '6' ), (int) 2 => array( 'subcategory_id' => '2', 'subcategory_name' => '知的財産', 'category_id' => '6' ), (int) 3 => array( 'subcategory_id' => '3', 'subcategory_name' => '経営マãƒã‚¸ãƒ¡ãƒ³ãƒˆ', 'category_id' => '6' ), (int) 4 => array( 'subcategory_id' => '4', 'subcategory_name' => 'ãã®ä»–', 'category_id' => '6' ) ) ) $category_sub_list = array( (int) 0 => array( 'CategoryMain' => array( 'category_id' => '1', 'category_name' => 'エレクトãƒãƒ‹ã‚¯ã‚¹ãƒ»IT' ), 'CategorySub' => array( (int) 0 => array( [maximum depth reached] ), (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ), (int) 6 => array( [maximum depth reached] ), (int) 7 => array( [maximum depth reached] ), (int) 8 => array( [maximum depth reached] ) ) ), (int) 1 => array( 'CategoryMain' => array( 'category_id' => '2', 'category_name' => 'メディカル・ãƒã‚¤ã‚ª' ), 'CategorySub' => array( (int) 0 => array( [maximum depth reached] ), (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ), (int) 6 => array( [maximum depth reached] ), (int) 7 => array( [maximum depth reached] ), (int) 8 => array( [maximum depth reached] ), (int) 9 => array( [maximum depth reached] ) ) ), (int) 2 => array( 'CategoryMain' => array( 'category_id' => '3', 'category_name' => 'ウエルãƒã‚¹' ), 'CategorySub' => array( (int) 0 => array( [maximum depth reached] ), (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ) ) ), (int) 3 => array( 'CategoryMain' => array( 'category_id' => '4', 'category_name' => '医療IT' ), 'CategorySub' => array( (int) 0 => array( [maximum depth reached] ), (int) 1 => array( [maximum depth reached] ) ) ), (int) 4 => array( 'CategoryMain' => array( 'category_id' => '5', 'category_name' => 'エãƒãƒ«ã‚®ãƒ¼ãƒ»ç’°å¢ƒ' ), 'CategorySub' => array( (int) 0 => array( [maximum depth reached] ), (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ), (int) 4 => array( [maximum depth reached] ), (int) 5 => array( [maximum depth reached] ), (int) 6 => array( [maximum depth reached] ) ) ), (int) 5 => array( 'CategoryMain' => array( 'category_id' => '6', 'category_name' => 'ビジãƒã‚¹ä¸€èˆ¬ãƒ»ãã®ä»–' ), 'CategorySub' => array( (int) 0 => array( [maximum depth reached] ), (int) 1 => array( [maximum depth reached] ), (int) 2 => array( [maximum depth reached] ), (int) 3 => array( [maximum depth reached] ) ) ) ) $category_main_list = array( (int) 1 => 'エレクトãƒãƒ‹ã‚¯ã‚¹ãƒ»IT', (int) 2 => 'メディカル・ãƒã‚¤ã‚ª', (int) 3 => 'ウエルãƒã‚¹', (int) 4 => '医療IT', (int) 5 => 'エãƒãƒ«ã‚®ãƒ¼ãƒ»ç’°å¢ƒ', (int) 6 => 'ビジãƒã‚¹ä¸€èˆ¬ãƒ»ãã®ä»–' ) $tax = '0.1' $content_for_layout = ' <style type="text/css"> @media screen and (min-width: 980px) { .report_patarn_license{ display:flex; } } .report_discription p { margin-bottom:10px; } .report_discription .details { margin-bottom:20px; } .report_discription .details h4 { padding:10px 0px; font-size:18px; border-top:1px solid #666; border-bottom:1px solid #666; margin:0px 0px 10px 0px; } .report_discription .details table { border-collapse:collapse; border-spacing:0px; width:100%; } .report_discription .details table th { background-color: #006dc3; background-color:lightblue; } .report_discription .details table th, .report_discription .details table td { /*border:1px solid #999; padding:5px;*/ /*border:none;*/ } /* table th,table td{ border:1px solid #999; padding:5px; } */ .report_discription .details .mu_table th, .report_discription .details .mu_table td { /*border:1px solid #999; padding:5px;*/ border:none; } .tooltip_favorite { position:absolute; left :800px; margin : 5px; display: inline-block; text-align: center; min-width: 120px; max-width: 100%; color: #006dc3; font-size: 16px; background: #fff; border : solid 1px; border-color : #005bb8; border-radius: 30px; } .sample_report{ border: none; background-color: transparent; font-size: 15px; color:#299cbd; cursor:pointer } .license_table{ empty-cells: show; border-right:1px solid #ccc; font-size:16px; margin:5px 5px; } .license_td{ text-align:center; vertical-align: middle; color:#fff; border-bottom:1px solid #ccc; background-color:#006dc3; border-bottom:1px solid #ccc; border-left:1px solid #ccc; border:1; height:50px; width:200px; font-size:15px; } .price_td{ text-align:center; vertical-align: middle; background-color:#fff; border-bottom:1px solid #ccc; border-right:1px solid #ccc; border:1; height:50px; width:200px; font-size:17px; } .format_td{ text-align:center; vertical-align: middle; background-color:#006dc3; border-bottom:1px solid #ccc; border-right:1px solid #ccc; border:1; height:50px; width:200px; font-size:17px; color:white; } .btn_cart_div{ display:flex; text-align:center; -webkit-justify-content: center; margin:20px 0px; padding:0px 50px; } </style> <div class="breadcrumb clearfix"> <ul> <li class="home"><a href="/">ホーム</a></li> <li><a href="/categories/index/?m_id=2">メディカル・ãƒã‚¤ã‚ª</a></li> <li>æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030</li> </ul> </div><!--/breadcrumb--> <div class="detail_main"> <form action="/categories/detail/39052?url=categories%2Fdetail%2F39052" id="detailForm" method="post" accept-charset="utf-8"><div style="display:none;"><input type="hidden" name="_method" value="POST"/></div> <div class="detail_mainIn"> <div class="detail_main_box"> <p class="report_number">レãƒãƒ¼ãƒˆãƒŠãƒ³ãƒãƒ¼ã€€0000039052</p> <div class="category"><a href="/categories/index/?m_id=2&s_id=1">医薬å“原料・製剤</a></div> <div class="category"><a href="/categories/index/?m_id=2&s_id=3">ç–¾ç—…åˆ¥æ²»ç™‚ãƒ»é ˜åŸŸåˆ¥æ²»ç™‚</a></div> <h3>æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030</h3> <p class="company">Grand View Research Inc.</p> <p class="subTitle"></p> <p class="subTitle"></p> <p class="subTitle">Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030</p> <div class="data"> <p><span>発刊日</span> 2024/07 <p><span>言語</span>英語</p> <p><span>体è£</span>PDF/175ページ</p> </div> </div><!--/detail_main_box--> <div class="detail_cart_area"> <div class="report_patarn clearfix"> <p class="report_patarnIn">ライセンス/ä¾¡æ ¼<span>175ページ</span></p> <p class="report_sub_number"> 0000039052 </p> </div> <div class="report_patarn_license clearfix"> <!--<p class="license_text"> æ€¥æ€§éª¨é«„æ€§ç™½è¡€ç—…æ²»ç™‚è–¬å¸‚å ´ï¼šè¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆã€ãŠã‚ˆã³ã‚»ã‚°ãƒ¡ãƒ³ãƒˆäºˆæ¸¬ã€2024〜2030<br> Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030 </p>--> <div class= "cart_div"> <table border=1 class="license_table"><!--<p class="license_price">--> <tbody> <!--<tr> <td class="license_td"> Individual </td> <td class="license_td"> Team </td> <td class="license_td"> Enterprise </td> </tr>--> <tr> <th class="license_td"> Individual </th> <td class="price_td"> <input type="radio" name="data[ReportBase][license]" class="license_radio" id="license" value="1" checked/> <label for="license">5,950USD</label><br> </td> </tr> <tr> <th class="license_td"> Team </th> <td class="price_td"> <input type="radio" name="data[ReportBase][license]" class="license_radio" id="license2" value="2" /> <label for="license2">6,950USD</label><br> </td> </tr> <tr> <th class="license_td"> Enterprise </th> <td class="price_td"> <input type="radio" name="data[ReportBase][license]" class="license_radio" id="license3" value="3" /> <label for="license3">8,950USD</label><br> </td> </tr> </tr> </tr> </tr> </tr> </tr> </tbody> </table><!--</p>--> </div> <div class="btn_cart_div"> <div class="btn_cart"> <input type="hidden" name="data[carts]" value="39052" id="carts"/> <button name="carts_add" id="carts_add">カートã¸</button> </div><!--/btn_cart--> <div class="btn_cart"> <input type="hidden" name="data[carts]" value="39052" id="carts"/> <button name="carts_now" id="carts_now">今ã™ã購入</button> </div><!--/btn_cart--> </div><!--/cart_div--> </div> </div><!--/detail_cart_area--> <p>※ã”請求ã¯ã€ãŠç”³è¾¼æ—¥ã®TTSレートã§å††æ›ç®—ã—ã€æ¶ˆè²»ç¨Žã‚’åŠ ãˆãŸé‡‘é¡ã«ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯ã€è‹±æ–‡ã§ã™ã€‚PDF(é›»å媒体)ã§ã®ç´å“ã¨ãªã‚Šã¾ã™ã€‚<br /> ※本レãƒãƒ¼ãƒˆã¯å–り寄ã›ã¨ãªã‚Šã¾ã™ã®ã§ã€ç”³ã—è¾¼ã¿ã‹ã‚‰ãŠå±Šã‘ã¾ã§ã€å¤šå°‘時間ãŒæŽ›ã‹ã‚‹å ´åˆãŒã”ã–ã„ã¾ã™ã€‚</p> <div class="btn_report_set"> <div class="btn01" style="margin:0px auto;"> <!--<button type="submit" class="contact" value="product_id">商å“ã‚’å•ã„åˆã‚ã›ã‚‹</button>--> <a href="https://www.spi-information.com/contacts/report_contact?report=39052&sample=0">ãŠå•ã„åˆã‚ã›</a> </div> <div class="btn01" style="margin:0px auto;"><a href="https://www.spi-information.com/contacts/report_contact?report=39052&sample=1">サンプルä¾é ¼</a></div> <button class="btn-form-cart" name="estimate" value="1">見ç©æ›¸ä½œæˆ</button> </div><!--/btn_report_set--> <div class="sample_box"> <p>無料サンプル</p> <ul> <li>サンプルã¯ãŠå•ã„åˆã‚ã›ãã ã•ã„。</li> </ul> </div><!--/sample_box--> <div class="report_discription"> <h3>レãƒãƒ¼ãƒˆæ¦‚è¦</h3> <p> <span style="font-weight:bold;">急性骨髄性白血病治療ã®å¸‚å ´è¦æ¨¡ã€ã‚·ã‚§ã‚¢ã€å‹•å‘分æžãƒ¬ãƒãƒ¼ãƒˆï¼šç–¾æ‚£åˆ¥ (骨髄芽çƒæ€§ç™½è¡€ç—…ã€éª¨é«„å˜çƒæ€§ç™½è¡€ç—…)ã€æ²»ç™‚別 (化å¦ç™‚法)ã€æŠ•ä¸ŽçµŒè·¯åˆ¥ã€æœ€çµ‚用途別ã€åœ°åŸŸåˆ¥ã€ã‚»ã‚°ãƒ¡ãƒ³ãƒˆåˆ¥äºˆæ¸¬ã€2024-2030 </span> </p> <p> <span style="font-weight:bold;">å¸‚å ´è¦æ¨¡ã¨å‹•å‘</span> </p> <p> 世界ã®æ€¥æ€§éª¨é«„性白血病治療薬ã®å¸‚å ´è¦æ¨¡ã¯ã€2023å¹´ã«31å„„8000万ドルã¨æŽ¨å®šã•ã‚Œã€2024å¹´ã‹ã‚‰2030å¹´ã«ã‹ã‘ã¦10.44%ã®CAGRã§æˆé•·ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚高度ãªæ²»ç™‚è–¬ã«å¯¾ã™ã‚‹ãƒ‹ãƒ¼ã‚ºã®é«˜ã¾ã‚Šã‚‚ã€ã“ã®å¸‚å ´ã«å¤§ããªå½±éŸ¿åŠ›ã‚’æŒã¤æŽ¨é€²è¦å› ã§ã™ã€‚急性骨髄性白血病治療薬ã®ç™ºç”ŸçŽ‡ã®ä¸Šæ˜‡ã¯ã€éºä¼å変異ã€ä¸å¥åº·ãªç”Ÿæ´»ç¿’æ…£ã€ãƒ™ãƒ³ã‚¼ãƒ³ãªã©ã®æœ‰å®³åŒ–å¦ç‰©è³ªã¸ã®ç¶™ç¶šçš„ãªæ›éœ²ã€æ”¾å°„線被ã°ããªã©ã®è¦å› ã«èµ·å› ã—ã¦ã„ã¾ã™ã€‚ã•ã‚‰ã«ã€é«˜é½¢è€…人å£ã®å¢—åŠ ã¨æº€ãŸã•ã‚Œã¦ã„ãªã„医療ニーズã®é«˜ã¾ã‚ŠãŒã€å¸‚å ´ã®æˆé•·ã‚’ã•ã‚‰ã«å¾ŒæŠ¼ã—ã™ã‚‹ã¨äºˆæƒ³ã•ã‚Œã¾ã™ã€‚2024å¹´ã«ç±³å›½ãŒã‚“å”会ãŒç™ºè¡¨ã—ãŸæŽ¨å®šã«ã‚ˆã‚‹ã¨ã€ç´„20,800人ãŒæ€¥æ€§éª¨é«„性白血病ã¨è¨ºæ–ã•ã‚Œã¾ã—ãŸã€‚ </p> <h3>レãƒãƒ¼ãƒˆè©³ç´°</h3> <div class="details"> <h4>目次</h4> <p> <span style="font-weight:bold;">Table of Contents</span> </p> <p> <span style="font-weight:bold;">Chapter 1. Methodology and Scope</span> <br /> 1.1. Market Segmentation & Scope<br /> 1.2. Segment Definitions<br /> 1.2.1. Disease<br /> 1.2.2. Treatment<br /> 1.2.3. Route of Administration<br /> 1.2.4. End Use<br /> 1.2.5. Regional scope<br /> 1.2.6. Estimates and forecasts timeline<br /> 1.3. Research Methodology<br /> 1.4. Information Procurement<br /> 1.4.1. Purchased database<br /> 1.4.2. GVR’s internal database<br /> 1.4.3. Secondary sources<br /> 1.4.4. Primary research<br /> 1.4.5. Details of primary research<br /> 1.4.5.1. Data for primary interviews in North America<br /> 1.4.5.2. Data for primary interviews in Europe<br /> 1.4.5.3. Data for primary interviews in Asia Pacific<br /> 1.4.5.4. Data for primary interviews in Latin America<br /> 1.4.5.5. Data for Primary interviews in MEA<br /> 1.5. Information or Data Analysis<br /> 1.5.1. Data analysis models<br /> 1.6. Market Formulation & Validation<br /> 1.7. Model Details<br /> 1.7.1. Commodity flow analysis (Model 1)<br /> 1.7.2. Approach 1: Commodity flow approach<br /> 1.7.3. Volume price analysis (Model 2)<br /> 1.7.4. Approach 2: Volume price analysis<br /> 1.8. List of Secondary Sources<br /> 1.9. List of Primary Sources<br /> 1.10. Objectives </p> <p> <span style="font-weight:bold;">Chapter 2. Executive Summary</span> <br /> 2.1. Market Outlook<br /> 2.2. Segment Outlook<br /> 2.2.1. Disease outlook<br /> 2.2.2. Treatment outlook<br /> 2.2.3. Route of Administration outlook<br /> 2.2.4. End Use outlook<br /> 2.2.5. Regional outlook<br /> 2.3. Competitive Insights </p> <p> <span style="font-weight:bold;">Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope</span> <br /> 3.1. Market Lineage Outlook<br /> 3.1.1. Parent market outlook<br /> 3.1.2. Related/ancillary market outlook<br /> 3.2. Market Dynamics<br /> 3.2.1. Market driver analysis<br /> 3.2.1.1. Increasing prevalence of acute myeloid leukemia<br /> 3.2.1.2. Advancements in diagnostic techniques<br /> 3.2.1.3. Growing investments in R&D techniques<br /> 3.2.2. Market restraint analysis<br /> 3.2.2.1. High cost of treatment<br /> 3.2.2.2. Limited treatment options<br /> 3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools<br /> 3.3.1. Industry Analysis - Porter’s Five Forces<br /> 3.3.1.1. Supplier power<br /> 3.3.1.2. Buyer power<br /> 3.3.1.3. Substitution threat<br /> 3.3.1.4. Threat of new entrant<br /> 3.3.1.5. Competitive rivalry<br /> 3.3.2. PESTEL Analysis<br /> 3.3.2.1. Political landscape<br /> 3.3.2.2. Technological landscape<br /> 3.3.2.3. Economic landscape<br /> 3.3.3. Pipeline Analysis </p> <p> <span style="font-weight:bold;">Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis</span> <br /> 4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard<br /> 4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis<br /> 4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue<br /> 4.4. Myeloblastic Leukemia<br /> 4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.5. Myelomonocytic Leukemia<br /> 4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.6. Promyelocytic Leukemia<br /> 4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.7. Monocytic Leukemia<br /> 4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 4.8. Other Diseases<br /> 4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis</span> <br /> 5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard<br /> 5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis<br /> 5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)<br /> 5.4. Chemotherapy<br /> 5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.2. Anti-metabolites<br /> 5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.3. Alkylating agents<br /> 5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.4. Anthracycline drugs<br /> 5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.4.5. Others<br /> 5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5. Targeted Therapy<br /> 5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2. FLT3 inhibitors<br /> 5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.1. Rydapt<br /> 5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.2. Vanflyta<br /> 5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.2.1.3. Xospata<br /> 5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3. IDH inhibitors<br /> 5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.1. Tibsovo<br /> 5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.2. Rezlidhia<br /> 5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.3.1.3. Idhifa<br /> 5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.4. Mylotarg<br /> 5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5. BCL-2 inhibitor<br /> 5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.5.1.1. Venclexta<br /> 5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6. Hedgehog pathway inhibitor<br /> 5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.5.6.1.1. Daurismo<br /> 5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6. Immunotherapy<br /> 5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.1. Bispecific antibodies<br /> 5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.2. Antibody-drug conjugates<br /> 5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.4. Immune checkpoint inhibitors<br /> 5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy<br /> 5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 5.7. Other Treatments<br /> 5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis</span> <br /> 6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard<br /> 6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis<br /> 6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)<br /> 6.4. Parenteral<br /> 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)<br /> 6.5. Oral<br /> 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis</span> <br /> 7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard<br /> 7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis<br /> 7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)<br /> 7.4. Hospital and Clinics<br /> 7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.5. Specialty Centers<br /> 7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)<br /> 7.6. Homecare Setting<br /> 7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration</span> <br /> 8.1. Regional Dashboard<br /> 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:<br /> 8.3. North America<br /> 8.3.1. U.S.<br /> 8.3.1.1. Key country dynamics<br /> 8.3.1.2. Regulatory framework/ reimbursement structure<br /> 8.3.1.3. Competitive scenario<br /> 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.2. Canada<br /> 8.3.2.1. Key country dynamics<br /> 8.3.2.2. Regulatory framework/ reimbursement structure<br /> 8.3.2.3. Competitive scenario<br /> 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.3.3. Mexico<br /> 8.3.3.1. Key country dynamics<br /> 8.3.3.2. Regulatory framework/ reimbursement structure<br /> 8.3.3.3. Competitive scenario<br /> 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4. Europe<br /> 8.4.1. UK<br /> 8.4.1.1. Key country dynamics<br /> 8.4.1.2. Regulatory framework/ reimbursement structure<br /> 8.4.1.3. Competitive scenario<br /> 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.2. Germany<br /> 8.4.2.1. Key country dynamics<br /> 8.4.2.2. Regulatory framework/ reimbursement structure<br /> 8.4.2.3. Competitive scenario<br /> 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.3. France<br /> 8.4.3.1. Key country dynamics<br /> 8.4.3.2. Regulatory framework/ reimbursement structure<br /> 8.4.3.3. Competitive scenario<br /> 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.4. Italy<br /> 8.4.4.1. Key country dynamics<br /> 8.4.4.2. Regulatory framework/ reimbursement structure<br /> 8.4.4.3. Competitive scenario<br /> 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.5. Spain<br /> 8.4.5.1. Key country dynamics<br /> 8.4.5.2. Regulatory framework/ reimbursement structure<br /> 8.4.5.3. Competitive scenario<br /> 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.6. Norway<br /> 8.4.6.1. Key country dynamics<br /> 8.4.6.2. Regulatory framework/ reimbursement structure<br /> 8.4.6.3. Competitive scenario<br /> 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.7. Sweden<br /> 8.4.7.1. Key country dynamics<br /> 8.4.7.2. Regulatory framework/ reimbursement structure<br /> 8.4.7.3. Competitive scenario<br /> 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.4.8. Denmark<br /> 8.4.8.1. Key country dynamics<br /> 8.4.8.2. Regulatory framework/ reimbursement structure<br /> 8.4.8.3. Competitive scenario<br /> 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5. Asia Pacific<br /> 8.5.1. Japan<br /> 8.5.1.1. Key country dynamics<br /> 8.5.1.2. Regulatory framework/ reimbursement structure<br /> 8.5.1.3. Competitive scenario<br /> 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.2. China<br /> 8.5.2.1. Key country dynamics<br /> 8.5.2.2. Regulatory framework/ reimbursement structure<br /> 8.5.2.3. Competitive scenario<br /> 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.3. India<br /> 8.5.3.1. Key country dynamics<br /> 8.5.3.2. Regulatory framework/ reimbursement structure<br /> 8.5.3.3. Competitive scenario<br /> 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.4. Australia<br /> 8.5.4.1. Key country dynamics<br /> 8.5.4.2. Regulatory framework/ reimbursement structure<br /> 8.5.4.3. Competitive scenario<br /> 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.5. South Korea<br /> 8.5.5.1. Key country dynamics<br /> 8.5.5.2. Regulatory framework/ reimbursement structure<br /> 8.5.5.3. Competitive scenario<br /> 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.5.6. Thailand<br /> 8.5.6.1. Key country dynamics<br /> 8.5.6.2. Regulatory framework/ reimbursement structure<br /> 8.5.6.3. Competitive scenario<br /> 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6. Latin America<br /> 8.6.1. Brazil<br /> 8.6.1.1. Key country dynamics<br /> 8.6.1.2. Regulatory framework/ reimbursement structure<br /> 8.6.1.3. Competitive scenario<br /> 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.6.2. Argentina<br /> 8.6.2.1. Key country dynamics<br /> 8.6.2.2. Regulatory framework/ reimbursement structure<br /> 8.6.2.3. Competitive scenario<br /> 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7. MEA<br /> 8.7.1. South Africa<br /> 8.7.1.1. Key country dynamics<br /> 8.7.1.2. Regulatory framework/ reimbursement structure<br /> 8.7.1.3. Competitive scenario<br /> 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.2. Saudi Arabia<br /> 8.7.2.1. Key country dynamics<br /> 8.7.2.2. Regulatory framework/ reimbursement structure<br /> 8.7.2.3. Competitive scenario<br /> 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.3. UAE<br /> 8.7.3.1. Key country dynamics<br /> 8.7.3.2. Regulatory framework/ reimbursement structure<br /> 8.7.3.3. Competitive scenario<br /> 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)<br /> 8.7.4. Kuwait<br /> 8.7.4.1. Key country dynamics<br /> 8.7.4.2. Regulatory framework/ reimbursement structure<br /> 8.7.4.3. Competitive scenario<br /> 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) </p> <p> <span style="font-weight:bold;">Chapter 9. Competitive Landscape</span> <br /> 9.1. Company/Competition Categorization<br /> 9.2. Vendor Landscape<br /> 9.2.1. List of key distributors and channel partners<br /> 9.2.2. Key customers<br /> 9.2.3. Key company market share analysis, 2023<br /> 9.2.4. Astellas Pharma Inc.<br /> 9.2.4.1. Company overview<br /> 9.2.4.2. Financial performance<br /> 9.2.4.3. Product benchmarking<br /> 9.2.4.4. Strategic initiatives<br /> 9.2.5. Bristol Myers Squibb Company<br /> 9.2.5.1. Company overview<br /> 9.2.5.2. Financial performance<br /> 9.2.5.3. Product benchmarking<br /> 9.2.5.4. Strategic initiatives<br /> 9.2.6. Celgene Corporation<br /> 9.2.6.1. Company overview<br /> 9.2.6.2. Financial performance<br /> 9.2.6.3. Product benchmarking<br /> 9.2.6.4. Strategic initiatives<br /> 9.2.7. Daiichi Sankyo Company, Limited<br /> 9.2.7.1. Company overview<br /> 9.2.7.2. Financial performance<br /> 9.2.7.3. Product benchmarking<br /> 9.2.7.4. Strategic initiatives<br /> 9.2.8. Jazz Pharmaceuticals, plc<br /> 9.2.8.1. Company overview<br /> 9.2.8.2. Financial performance<br /> 9.2.8.3. Product benchmarking<br /> 9.2.8.4. Strategic initiatives<br /> 9.2.9. Novartis AG<br /> 9.2.9.1. Company overview<br /> 9.2.9.2. Financial performance<br /> 9.2.9.3. Product benchmarking<br /> 9.2.9.4. Strategic initiatives<br /> 9.2.10. Otsuka Pharmaceuticals Co., Ltd.<br /> 9.2.10.1. Company overview<br /> 9.2.10.2. Financial performance<br /> 9.2.10.3. Product benchmarking<br /> 9.2.10.4. Strategic initiatives<br /> 9.2.11. Pfizer, Inc.<br /> 9.2.11.1. Company overview<br /> 9.2.11.2. Financial performance<br /> 9.2.11.3. Product benchmarking<br /> 9.2.11.4. Strategic initiatives<br /> 9.2.12. Rigel Pharmaceuticals, Inc.<br /> 9.2.12.1. Company overview<br /> 9.2.12.2. Financial performance<br /> 9.2.12.3. Product benchmarking<br /> 9.2.12.4. Strategic initiatives<br /> 9.2.13. Merck & Co., Inc.<br /> 9.2.13.1. Company overview<br /> 9.2.13.2. Financial performance<br /> 9.2.13.3. Product benchmarking<br /> 9.2.13.4. Strategic initiatives<br /> 9.2.14. Sanofi<br /> 9.2.14.1. Company overview<br /> 9.2.14.2. Financial performance<br /> 9.2.14.3. Product<br /> 9.2.14.4. Benchmarking<br /> 9.2.14.5. Strategic initiatives </p> <p> <span style="font-weight:bold;">List of Tables</span> <br /> Table 1 List of abbreviation<br /> Table 2 North America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 3 North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 4 North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 5 North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 6 North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 7 U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 8 U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 9 U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 10 U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 11 Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 12 Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 13 Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 14 Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 15 Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 16 Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 17 Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 18 Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 19 Europe acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 20 Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 21 Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 22 Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 23 Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 24 Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 25 Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 26 Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 27 Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 28 UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 29 UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 30 UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 31 UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 32 France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 33 France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 34 France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 35 France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 36 Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 37 Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 38 Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 39 Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 40 Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 41 Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 42 Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 43 Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 44 Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 45 Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 46 Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 47 Denmark Acute Myeloid Leukemia Treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 48 Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 49 Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 50 Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 51 Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 52 Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 53 Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 54 Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 55 Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 56 Asia Pacific acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 57 Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 58 Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 59 Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 60 Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 61 China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 62 China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 63 China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 64 China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 65 Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 66 Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 67 Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 68 Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 69 India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 70 India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 71 India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 72 India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 73 South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 74 South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 75 South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 76 South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 77 Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 78 Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 79 Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 80 Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 81 Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 82 Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 83 Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 84 Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 85 Latin America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 86 Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 87 Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 88 Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 89 Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 90 Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 91 Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 92 Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 93 Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 94 Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 95 Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 96 Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 97 Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 98 MEA acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)<br /> Table 99 MEA acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 100 MEA acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 101 MEA acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 102 MEA acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 103 South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 104 South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 105 South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 106 South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 107 Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 108 Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 109 Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 110 Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 111 UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 112 UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 113 UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 114 UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)<br /> Table 115 Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)<br /> Table 116 Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)<br /> Table 117 Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)<br /> Table 118 Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million) </p> <p> <span style="font-weight:bold;">List of Figures</span> <br /> Fig. 1 Market research process<br /> Fig. 2 Data triangulation techniques<br /> Fig. 3 Primary research pattern<br /> Fig. 4 Primary interviews in North America<br /> Fig. 5 Primary interviews in Europe<br /> Fig. 6 Primary interviews in APAC<br /> Fig. 7 Primary interviews in Latin America<br /> Fig. 8 Primary interviews in MEA<br /> Fig. 9 Market research approaches<br /> Fig. 10 Value-chain-based sizing & forecasting<br /> Fig. 11 QFD modeling for market share assessment<br /> Fig. 12 Market formulation & validation<br /> Fig. 13 Acute myeloid leukemia treatment market: market outlook<br /> Fig. 14 Acute myeloid leukemia treatment competitive insights<br /> Fig. 15 Parent market outlook<br /> Fig. 16 Related/ancillary market outlook<br /> Fig. 17 Acute myeloid leukemia treatment market driver impact<br /> Fig. 18 Acute myeloid leukemia treatment market restraint impact<br /> Fig. 19 Acute myeloid leukemia treatment market: disease movement analysis<br /> Fig. 20 Acute myeloid leukemia treatment market: disease outlook and key takeaways<br /> Fig. 21 Myeloblastic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 22 Myelomonocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 23 Promyelocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 25 Monocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 26 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 27 Acute myeloid leukemia treatment market: Treatment movement analysis<br /> Fig. 28 Acute myeloid leukemia treatment market: Treatment outlook and key takeaways<br /> Fig. 29 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 30 Anti-metabolites market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 31 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 32 Anthracycline drugs market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 34 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 35 FLT3 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 36 Rydapt market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 37 Vanflyta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 38 Xospata market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 39 IDH inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 40 Tibsovo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 41 Rezlidhia market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 42 Idhifa market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 43 Mylotarg market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 44 BCL-2 inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 45 Venclexta market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 46 Hedgehog pathway inhibitor market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 47 Daurismo market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 48 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 49 Bispecific antibodies market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 50 Antibody-drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 51 Immune checkpoint inhibitors market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 52 Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 53 Other treatments market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 54 Acute myeloid leukemia treatment market: Route of administration movement analysis<br /> Fig. 55 Acute myeloid leukemia treatment market: Route of administration outlook and key takeaways<br /> Fig. 56 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 57 Oral market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 58 Acute myeloid leukemia treatment market: End Use movement analysis<br /> Fig. 59 Acute myeloid leukemia treatment market: End Use outlook and key takeaways<br /> Fig. 60 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 61 Specialty centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 62 Homecare setting market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 63 Ambulatory care centers market estimates and forecast, 2018 - 2030 (USD Million)<br /> Fig. 64 Global acute myeloid leukemia treatment market: Regional movement analysis<br /> Fig. 65 Global acute myeloid leukemia treatment market: Regional outlook and key takeaways<br /> Fig. 66 Global acute myeloid leukemia treatment market share and leading players<br /> Fig. 67 North America, by country<br /> Fig. 68 North America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 69 U.S. key country dynamics<br /> Fig. 70 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 71 Canada key country dynamics<br /> Fig. 72 Canada market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 73 Mexico key country dynamics<br /> Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 75 Europe market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 76 UK key country dynamics<br /> Fig. 77 UK market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 78 Germany key country dynamics<br /> Fig. 79 Germany market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 80 France key country dynamics<br /> Fig. 81 France market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 82 Italy key country dynamics<br /> Fig. 83 Italy market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 84 Spain key country dynamics<br /> Fig. 85 Spain market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 86 Denmark key country dynamics<br /> Fig. 87 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 88 Sweden key country dynamics<br /> Fig. 89 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 90 Norway key country dynamics<br /> Fig. 91 Norway market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 93 China key country dynamics<br /> Fig. 94 China market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 95 Japan key country dynamics<br /> Fig. 96 Japan market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 97 India key country dynamics<br /> Fig. 98 India market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 99 Thailand key country dynamics<br /> Fig. 100 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 101 South Korea key country dynamics<br /> Fig. 102 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 103 Australia key country dynamics<br /> Fig. 104 Australia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 105 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 106 Brazil key country dynamics<br /> Fig. 107 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 108 Argentina key country dynamics<br /> Fig. 109 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 110 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 111 South Africa key country dynamics<br /> Fig. 112 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 113 Saudi Arabia key country dynamics<br /> Fig. 114 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 115 UAE key country dynamics<br /> Fig. 116 UAE market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 117 Kuwait key country dynamics<br /> Fig. 118 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)<br /> Fig. 119 Market share of key market players- acute myeloid leukemia treatment market </p> </div> </div><!--/report_discription--> <div class="btn_report_set"> <div class="btn01"> <a href="/guides">ãŠè²·ã„物ガイド</a> </div><!--/btn01--> <div class="btn01"> <a href="/questions">よãã‚る質å•</a> </div><!--/btn01--> </div><!--/btn_report_set--> <div class="tel_guide clearfix"> <a href="tel:0358125270"><img src="/img/./category/suport_tel_03.jpg" alt=""/></a> <div class="report_no"> <p>ã“ã®å•†å“ã®ãƒ¬ãƒãƒ¼ãƒˆãƒŠãƒ³ãƒãƒ¼</p> <p class="report_no_box">0000039052</p> </div> </div><!--/tel_guide--> </div> </form> </div> <script type="text/javascript"> $('#carts_add').css("cursor","pointer"); $('#carts_now').css("cursor","pointer"); $('#heart_off').css("cursor","pointer"); $('.heart_off').css("cursor","pointer"); $(function(){ if($('#stlist').length){ $('.btn_cart').fadeOut(); } }); $(function () { $('.tooltip_favorite').hide(); $('div').hover( function () { $(this).children('.tooltip_favorite').fadeIn('fast'); }, function () { $(this).children('.tooltip_favorite').fadeOut('fast'); }); }); </script> ' $scripts_for_layout = '' $title_for_layout = 'Categories'header - [internal], line ?? include - APP/View/Layouts/spi-information.ctp, line 2 View::_evaluate() - CORE/Cake/View/View.php, line 971 View::_render() - CORE/Cake/View/View.php, line 933 View::renderLayout() - CORE/Cake/View/View.php, line 546 View::render() - CORE/Cake/View/View.php, line 481 Controller::render() - CORE/Cake/Controller/Controller.php, line 968 Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 200 Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167 [main] - APP/webroot/index.php, line 118
Copyright c SPI Information,Inc. 2019 All rights reserved.
Warning (2): Unknown: open(/tmp//sess_b61c765e8dfd0e2cf6d6b2bc70fff848, O_RDWR) failed: Disc quota exceeded (69) [Unknown, line 0]Code Context$GLOBALS = array( 'GLOBALS' => [recursion], '_ENV' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ), 'HTTP_ENV_VARS' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ), '_POST' => array(), 'HTTP_POST_VARS' => array(), '_GET' => array( 'url' => 'categories/detail/39052' ), 'HTTP_GET_VARS' => array( 'url' => 'categories/detail/39052' ), '_COOKIE' => array(), 'HTTP_COOKIE_VARS' => array(), '_SERVER' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ), 'HTTP_SERVER_VARS' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ), '_FILES' => array(), 'HTTP_POST_FILES' => array(), '_REQUEST' => array( 'url' => 'categories/detail/39052' ), 'vendorPath' => '/home/spi-information/www/app/Vendor/cakephp/cakephp/lib', 'dispatcher' => 'Cake/Console/ShellDispatcher.php', 'encoding' => 'UTF-8', 'Dispatcher' => object(Dispatcher) { [protected] _eventManager => object(CakeEventManager) {} }, 'HTTP_SESSION_VARS' => array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) ), '_SESSION' => array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) ) ) $_ENV = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ) $HTTP_ENV_VARS = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ) $_POST = array() $HTTP_POST_VARS = array() $_GET = array( 'url' => 'categories/detail/39052' ) $HTTP_GET_VARS = array( 'url' => 'categories/detail/39052' ) $_COOKIE = array() $HTTP_COOKIE_VARS = array() $_SERVER = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ) $HTTP_SERVER_VARS = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ) $_FILES = array() $HTTP_POST_FILES = array() $_REQUEST = array( 'url' => 'categories/detail/39052' ) $vendorPath = '/home/spi-information/www/app/Vendor/cakephp/cakephp/lib' $dispatcher = 'Cake/Console/ShellDispatcher.php' $encoding = 'UTF-8' $Dispatcher = object(Dispatcher) { [protected] _eventManager => object(CakeEventManager) {} } $HTTP_SESSION_VARS = array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) ) $_SESSION = array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) )session_write_close - [internal], line ?? [main] - [internal], line ??
Warning (2): Unknown: Failed to write session data (files). Please verify that the current setting of session.save_path is correct () [Unknown, line 0]Code Context$GLOBALS = array( 'GLOBALS' => [recursion], '_ENV' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ), 'HTTP_ENV_VARS' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ), '_POST' => array(), 'HTTP_POST_VARS' => array(), '_GET' => array( 'url' => 'categories/detail/39052' ), 'HTTP_GET_VARS' => array( 'url' => 'categories/detail/39052' ), '_COOKIE' => array(), 'HTTP_COOKIE_VARS' => array(), '_SERVER' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ), 'HTTP_SERVER_VARS' => array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ), '_FILES' => array(), 'HTTP_POST_FILES' => array(), '_REQUEST' => array( 'url' => 'categories/detail/39052' ), 'vendorPath' => '/home/spi-information/www/app/Vendor/cakephp/cakephp/lib', 'dispatcher' => 'Cake/Console/ShellDispatcher.php', 'encoding' => 'UTF-8', 'Dispatcher' => object(Dispatcher) { [protected] _eventManager => object(CakeEventManager) {} }, 'HTTP_SESSION_VARS' => array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) ), '_SESSION' => array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) ) ) $_ENV = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ) $HTTP_ENV_VARS = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php' ) $_POST = array() $HTTP_POST_VARS = array() $_GET = array( 'url' => 'categories/detail/39052' ) $HTTP_GET_VARS = array( 'url' => 'categories/detail/39052' ) $_COOKIE = array() $HTTP_COOKIE_VARS = array() $_SERVER = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ) $HTTP_SERVER_VARS = array( 'PHPRC' => '/home/spi-information/www', 'PATH' => '/usr/local/bin:/usr/bin:/bin', 'REDIRECT_STATUS' => '200', 'HTTPS' => 'on', 'HTTP_AUTHORIZATION' => '', 'HTTP_HOST' => 'www.spi-information.com', 'HTTP_X_REAL_IP' => '18.216.186.122', 'HTTP_LISTEN_IPADDR' => '133.167.8.188', 'HTTP_PRAGMA' => 'no-cache', 'HTTP_CACHE_CONTROL' => 'no-cache', 'HTTP_SEC_CH_UA' => '"Chromium";v="130", "HeadlessChrome";v="130", "Not?A_Brand";v="99"', 'HTTP_SEC_CH_UA_MOBILE' => '?0', 'HTTP_SEC_CH_UA_PLATFORM' => '"Windows"', 'HTTP_UPGRADE_INSECURE_REQUESTS' => '1', 'HTTP_USER_AGENT' => 'Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)', 'HTTP_ACCEPT' => 'text/html,application/xhtml+xml,application/xml;q=0.9,image/avif,image/webp,image/apng,*/*;q=0.8,application/signed-exchange;v=b3;q=0.7', 'HTTP_SEC_FETCH_SITE' => 'none', 'HTTP_SEC_FETCH_MODE' => 'navigate', 'HTTP_SEC_FETCH_USER' => '?1', 'HTTP_SEC_FETCH_DEST' => 'document', 'HTTP_ACCEPT_ENCODING' => 'gzip, deflate, br, zstd', 'HTTP_PRIORITY' => 'u=0, i', 'SERVER_SIGNATURE' => '', 'SERVER_SOFTWARE' => 'Apache', 'SERVER_NAME' => 'www.spi-information.com', 'SERVER_ADDR' => '100.64.0.57', 'SERVER_PORT' => '443', 'REMOTE_HOST' => 'ec2-18-216-186-122.us-east-2.compute.amazonaws.com', 'REMOTE_ADDR' => '18.216.186.122', 'DOCUMENT_ROOT' => '/home/spi-information/www/', 'REQUEST_SCHEME' => 'https', 'CONTEXT_PREFIX' => '', 'CONTEXT_DOCUMENT_ROOT' => '/home/spi-information/www/', 'SERVER_ADMIN' => '[no address given]', 'SCRIPT_FILENAME' => '/home/spi-information/www/app/webroot/index.php', 'REMOTE_PORT' => '0', 'REDIRECT_URL' => '/app/webroot/categories/detail/39052', 'REDIRECT_QUERY_STRING' => 'url=categories/detail/39052', 'GATEWAY_INTERFACE' => 'CGI/1.1', 'SERVER_PROTOCOL' => 'HTTP/1.1', 'REQUEST_METHOD' => 'GET', 'QUERY_STRING' => 'url=categories/detail/39052', 'REQUEST_URI' => '/categories/detail/39052', 'SCRIPT_NAME' => '/app/webroot/index.php', 'PHP_SELF' => '/app/webroot/index.php', 'REQUEST_TIME' => (int) 1748713137, 'argv' => array( (int) 0 => 'url=categories/detail/39052' ), 'argc' => (int) 1 ) $_FILES = array() $HTTP_POST_FILES = array() $_REQUEST = array( 'url' => 'categories/detail/39052' ) $vendorPath = '/home/spi-information/www/app/Vendor/cakephp/cakephp/lib' $dispatcher = 'Cake/Console/ShellDispatcher.php' $encoding = 'UTF-8' $Dispatcher = object(Dispatcher) { [protected] _eventManager => object(CakeEventManager) {} } $HTTP_SESSION_VARS = array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) ) $_SESSION = array( 'Config' => array( 'userAgent' => 'dc9e586010a78aa48b50058743b65b01', 'time' => (int) 1904233137, 'countdown' => (int) 10 ), 'CheckedReports' => array( (int) 0 => '39052' ) )session_write_close - [internal], line ?? [main] - [internal], line ??
